CURRICULUM VITAE Robert H. Christenson, Ph.D., DABCC, FACB

Professor, with tenure, Department of PathologyUniversity of Maryland, School of Medicine

Laboratories of PathologyUniversity of Maryland School of Medicine

22 South Greene StreetBaltimore, Maryland 21201

Primary AppointmentProfessorDepartment of PathologyUniversity of Maryland School of Medicine

Secondary AppointmentProfessorDepartment of Medical and Research TechnologyUniversity of Maryland School of Medicine

Education

B.A. University of Massachusetts Chemistry 1976Ph.D. Florida State University Chemistry, Concentration: Analytical Chemistry 1980Fellow University of North Carolina Laboratory Medicine 1980-1982Certifications

Certified Diplomate, American Board of Clinical Chemistry 8/1/1984 certificate number 724Fellow, Academy of Clinical Biochemistry 1993

Major Research Interests

Biochemical markers for assessing cell injury: Ongoing activities include the investigation of markers for evaluation of acute coronary syndromes, early diagnosis of acute myocardial infarction, the noninvasive biochemical assessment of successful reperfusion, and characterizing the release and metabolism of biochemical markers after shock and other forms of cell injury.

Laboratory-assisted diagnosis of neurologic diseases: Activities include defining the performance characteristics of assays used for diagnosing and monitoring neurologic diseases. Investigate new markers and marker panels for the diagnosis, treatment and monitoring of stroke.

Improved strategies for utilization of laboratory tests: Interests include new ways that the clinical laboratory can provide diagnostic information to clinicians.

Monitoring Markers of Bone Metabolism: Activities include investigating new markers of bone metabolism and improving assays for diagnosis and monitoring of patients with osteoporosis and other bone disorders.

Evidence Based Medicine: Participating and conducting evidence reviews on topics in laboratory medicine and utilizing them in best practice development and guideline formulation is a major professional focus.

Employment History

Teaching Assistant, Florida State University, Tallahassee, FL 1976-1980Research Assistant, Florida State University, Tallahassee, FL 1978-1979Postdoctoral Fellow in Clinical Chemistry, University of North Carolina, Chapel Hill, NC 1980-1982Assistant Professor, Depart. of Pathology, Duke University Medical Center, Durham, NC 1982-1991Associate Professor (tenure track), Department of Pathology, University of Maryland School of Medicine, Baltimore, MD

1991-1992

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 2

Associate Professor (with tenure), Department of Pathology, University of Maryland School of Medicine, Baltimore, MD

1992-1997

Professor (with tenure), Department of Pathology, University of Maryland School of Medicine, Baltimore, MD

1997-present

Professor, Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD

1998-present

Major Academic Tasks

Director, Clinical Chemistry and Urinalysis Laboratories, Durham Veterans Administration (VA) Medical Center, Durham, NC

1982-1991

Director, Pathology Residency Training in Clinical Chemistry at the Durham VA Medical Center, Durham, NC

1982-1991

Co-Director, Clinical Chemistry activities in the Medical Technology Program, Duke University Medical Center, Durham, NC

1982-1991

Director, Special Chemistry Laboratory, Duke University Medical Center, Durham, NC 1986-1991Co-Director, CSF TRAP Laboratory, Duke University Medical Center, Durham, NC 1987-1989Director, CSF TRAP Laboratory, Duke University Medical Center, Durham, NC 1989-1991Director, Clinical Chemistry Laboratories, University of Maryland Medical Center, University of Maryland Medical Systems, Baltimore, MD

1991-present

Director, Clinical Chemistry Research Laboratory, 8th Floor, Bressler Research Building, Baltimore, MD

1991-present

Director, Postdoctoral Training Program at the University of Maryland School of Medicine; this program is approved by the Commission on Accreditation in Clinical Chemistry (or ComACC)

1991-present

Director, Pathology Residency Training in Clinical Chemistry, University of Maryland School of Medicine, Baltimore, MD

1991-present

Director, Clinical Chemistry Tracts, Graduate Training Programs in Pathology, University of Maryland School of Medicine, Baltimore, MD

1991-present

Technical Director of Clinical Chemistry, Associates in Pathology, University of Maryland School of Medicine, Baltimore, MD

1991-present

Associate Member, Graduate Faculty, University of Maryland, Baltimore, MD 1991-1997Technical Supervisor, Edmondson Village University Care Laboratory 1994-2000Chief, Laboratory Informatics, Laboratories of Pathology, UMMC 1995-presentDirector, Point of Care Testing, University of Maryland Medical Center, Baltimore, MD (Under Separate State of Maryland License with Dr. Christenson as director)

1995-present

Director, Shock Trauma Center Laboratory, University of Maryland Medical Center, Baltimore, MD

1995-present

Director, Rapid Response Laboratory, University of Maryland Medical Center, Baltimore, MD

1996-present

Member, Graduate Faculty, University of Maryland, Baltimore, MDMember, University of Maryland Medical School Admissions Committee

1997-present2004-2012

Member, Appointments, promotion and tenure committee for Pathology 2004-2013Chair, Appointments, promotion and tenure committee for Pathology 2014-presentNominating Committee International Federation for Clinical Chemistry 2015-presentEditor in Chief, Journal of Applied Laboratory Medicine, AACC Publication 2016-present

Professional Memberships

Member, American Association for Clinical Chemistry (AACC) 1977-presentAssociate Member, Sigma Xi 1979-1981Member, Sigma Xi 1985-presentMember, American Heart Association – Basic Science 1990-present

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 3

Honors and Awards

Graduated Cum Laude, University of Massachusetts, Amherst, Massachusetts 1976Travel Grant Recipient, Education Committee of the American Association for Clinical Chemistry

1978

Appointed to Abstracts Review Committee, 1985 Organizing Committee for the National Meeting of the American Association for Clinical Chemistry

1984-1985

Nominated and elected Chairman, North Carolina Section of American Association for Clinical Chemistry

1985-1986

Nominated and elected to the Nominating Committee, North Carolina Section of the American Association for Clinical Chemistry

1989-1991

Nominated and appointed Member, Government Relations Committee for the American Association for Clinical Chemistry

1986-1992

Nominated, Young Investigator Award – American Association for Clinical Chemistry 1988Nominated and appointed, Roundtables Chairman, 1991 Organizing Committee for the National Meeting of the American Association for Clinical Chemistry

1990

Research on myocardial cell injury was designated for press coverage at the 1990 National Meeting by the American Association for Clinical Chemistry

1990-1991

Appointed to editorial board of Clinical Chemistry News 1991Appointed Chairman, Board of Editors for Clinical Chemistry News 1992-1995Elected Chairman, American Association of Clinical Chemistry-Capital Section 1992Keynote Speaker, graduation ceremony for the Medical Technology Program, University of Maryland School of Medicine

1993

Interviewed on WBAL regarding work in biochemical markers of myocardial infarction 1994Who’s Who in America citation 1995-presentJoseph H. Roe Award for Recognition of Contributions in Clinical Chemistry, Capital Section, AACC

1998

Norman Kubasik Award for Outstanding Contributions to the Education of Clinical Laboratory Scientists, NY Upstate Section, AACC

2000

Bernard F. Gerulat Memorial Award Outstanding Achievements in Clinical Chemistry, New Jersey Section, AACC

2000

Appointed as expert for a Stanford Evidence Practice Center Review on Heart Disease (AHRQ)

3/01-present

Elected to Board of Directors, American Association of Clinical Chemistry 1999-20018th Annual Roger Boeckx Award and Memorial Lecture, AACC Capital Section 2002-2004Named by Secretary of Veterans Affairs to Blue Ribbon Panel on Cardiology Services within VA system

2003-2004

Appointed to Medicare Coverage Advisory Committee; Center for Medicare & Medicaid Services, Department of Health & Human Services

2004

Awarded Transatlantic Lectureship; Association of Clinical Biochemists, United Kingdom 2004Awarded Roy N. Barnett, MD Memorial Lectureship, Norwalk Hospital, Norwalk, CT 2004Appointed Chair, Committee for Laboratory Medicine Practice Guidelines on Cardiac Biomarkers of Acute Coronary Syndromes and Heart Failure; National Academy of Clinical Biochemistry

2004

Served as Chair, 2004 Arnold O. Beckman Conference, Cambridge, Massachusetts, Cardiac Biomarker Guidelines of Acute Coronary Syndrome and Heart Failure

2004

Selected for inclusion in the academic Keys Who's Who in Medical Sciences Education (WWMSE): Academic Keys Who's Who in Medical Sciences Education is the most comprehensive and authoritative online source available on leading and influential experts and scientists in the field of Medical Sciences in the institutes of higher education.

2004

NACB Presidential Citation for successful 2004 Beckman Meeting 2005National Award for Outstanding Contributions in Education, American Association for 2005

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 4

Clinical Chemistry, Awarded Spinoza Lectureship and Visiting Professorship, Academic Medical Center, Amsterdam, The Netherlands

2005

TransAtlantic Lectureship Award, Association of Clinical Biochemists, UK 2004Named Vice Chair, NACB Laboratory Medicine Practice Guideline on Emerging Markers of Cardiovascular Risk International Lectureship Award, Australian Association for Clinical Chemistry 2006Roy Barnett Award for Contributions to Clinical Chemistry, Norwalk Hospital, Norwalk, CT 2007AACC Speaker Award, each year 1999-presentElected President, American Association for Clinical Chemistry 2011Meyer Bodansky Visiting Professor of Experimental Pathology, UTMB, Galveston, TX 2014Elected, Nominating Committee, American Association for Clinical Chemistry 2016Appointed, Laboratory Best Practices Oversight Committee, CDC, Atlanta, GA 2007 to presentVisiting Professor, Cleveland Clinic, Cleveland Ohio 2017

Institutional Service

Duke University/Durham VA Medical Centers

Chairman, Laboratory Computer Implementation Group, Durham VA Medical Center, Durham, NC

1985-1988

Member, Laboratory Utilization Review Committee, Durham VA Medical Center, Durham, NC

1985-1989

Chairman, Laboratory Utilization Review Committee, Durham VA Medical Center, Durham, NC

1989-1991

Member, Critical Care Committee, Durham VA Medical Center, Durham, NC 1989-1991Member, Hospital Utilization Review Committee, Durham VA Medical Center, Durham, NC

1989-1991

Member, Medical Radioisotope and Radiation Control Committee, Durham VA Medical Center, Durham, NC

1986

Co-founder of CSF Bank, Duke University. The CSF Bank serves as a fully-databased repository for spinal fluid left over from routine studies.

1986

Director, Ancillary Testing, Durham VA Medical Center, Durham, NC 1987-1991

University of Maryland, Baltimore

Member, Technology Management Committee, University of Maryland Medical Systems, Baltimore, MD

1991-present

Interviewer, Medical School Applicants, University of Maryland School of Medicine, Baltimore, MD

1991, 1992

Member, Critical Care Committee, University of Maryland Medical Systems, Baltimore, MD

1991-present

Pathology Representative, School of Medicine Council, University of Maryland School of Medicine, Baltimore, MD

1991-present

Search Committee, State of Maryland Chief Toxicologist 1992Search Committee, Director of Hospital Laboratories 1992Team Leader, Patient Discharge Committee, UMMS Service Quality Management Program

1992-present

Member, Search Committee for Chemistry Discipline Director, Department of Medical and Research Technology

1994

Pathology Representative, School of Medicine Council, University of Maryland School of Medicine, Baltimore, MD

1996-1997

Member, Pathology Residency Training Committee 1996-presentMember, Medical School Admissions Committee, University of Maryland School of 2005-presentMedicine

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 5

Editorial Tasks

Reviewer, Clinical Chemistry (Washington, DC) 1983-presentReviewer, Analytical Chemistry (Washington, DC) 1983-presentGuest Editor, Laboratory Consultant Section, Clinical Chemistry News, (Washington, DC) 1987-1988Editorial Advisory Board, Clinical Chemistry News 1988-1990Reviewer, Clinical Chemistry News, (Washington, DC) 1989-presentMember, Editorial Board of Clinical Chemistry News, (Washington, DC) 1991-presentReviewer, Journal of Clinical Immunoassay, (Detroit, MI) 1991-presentChair, Editorial Board, Clinical Laboratory News, (Washington, DC) 1992-1997Chair, Editorial Advisory Board, Clinical Laboratory News, (Washington, DC) 1990-1992Member, Editorial Board, Clinical Biochemistry, (Alberta, Canada) 1995-presentReviewer, American Heart Journal, (Durham, NC) 1996-presentReviewer, Journal of the American College of Cardiology, (Houston, TX) 1995-presentReviewer, Mikrochimica Acta, (Surrey, United Kingdom) 1996-presentMember, Board of Editors, Journal of Clinical Laboratory Analysis, (Richmond, VA) 1996-presentMember, Board of Editors, Clinical Chemistry, (Washington, DC) 1998-presentReviewer, Circulation, (Dallas, TX) 1997-presentReviewer, Clinical Chemistry and Laboratory Medicine, (Berlin, Germany) 1998-presentReviewer, American Journal of Obstetrics and Gynecology, (Columbus, OH) 1999-presentReviews Editor, Clinical Biochemistry 2002-presentMember, Board of Editors, Clinical Proteomics (Washington, DC) 2003-presentReviews Editor, Clinical Biochemistry (Alberta, Canada) 2001-2003Associate Editor, Clinical Biochemistry (Toronto, Canada) 2003-present

Membership Activities, National and International

Member, Government Relations Committee, American Association for Clinical Chemistry, 1984-1987Representative, Public Issues Committee, American Association for Clinical Chemistry, Washington, DC 1990-1994Member, Committee for Standardizing Creatine Kinase-MB Mass Assays, American Association for Clinical Chemistry

1991-1995

Organizing Committee, Clinical Chemistry Review Course, American Association for Clinical Chemistry, Washington, DC

1992-1994

Co-Chairman, Clinical Chemistry Review Course, American Association for Clinical Chemistry, Washington, DC

1994-present

Member to the Coordinating Committee of the National Heart Attack Alert Program, sponsored by the National Institutes of Health

1995-present

Member, Planning Committee for the 5-year Retreat for the National Heart Attack Alert Program, sponsored by the National Institutes of Health

1996

Organizing committee for the 1997 National Meeting for the American Association for Clinical Chemistry, to be held in Atlanta, GA. Directing Plenary Sessions.

1996-present

Member, International Committee for Standardizing Cardiac Troponin I Assays, sponsored by the American Association for Clinical Chemistry

1998-2003

Chair, Organizing Committee for the 1999 American Association for Clinical Chemistry Annual Laboratory Exposition and Meeting, New Orleans, LA

1997-1999

Member, IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD) 1998-presentChair, Evidence Based Medicine Group, AACC (made a committee in 2005) 2001Chair, Evidence Based Medicine Committee, AACC 2005-presentMember, IFCC Committee for Evidence Based Laboratory Medicine (EBLM) 2003-presentNIH Study Section SBIR Grants 2006Study Section National Science Foundation 2007Reviewer, CDC/Battelle Defining Best Practices in Laboratory Medicine 2006-presentMember, CDC New Era Panel 2007

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 6

Teaching Responsibilities

University of Maryland, Baltimore

Attending Faculty Member, Resident’s Journal Club 1991Selected Topics in Pathology (for Residents), “Serum Protein Electrophoresis: Laboratory Methods and Interpretation”

1991

Director of Approved Postdoctoral Training Program in Clinical Chemistry, University of Maryland School of Medicine

1991-present

Lecturer, Sophomore Pathology (Medical Students) PATH 520, University of Maryland, Baltimore

1991-present

Director, Clinical Chemistry Courses (751, 752, 753, and 754), University of Maryland, Baltimore

1991-present

Program coordinator, ComACC accredited Master of Science program: concentration in Clinical Chemistry, University of Maryland School of Medicine, Department of Pathology

1991-present

Invited Lecturer, Department of Medical and Research Technology 1992, 1993Invited Lecturer, Clinical Laboratory Management Course, Department of Medical and Research Technology

1993-present

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 7

Publications

Monographs

1. Christenson, R.H. Improved methods of quantitation for the metanephrines in the laboratory-assisted diagnosis of pheochromocytoma. (Ph.D. Dissertation), July, 1980.

2. Christenson, R.H. Glycated Hemoglobin A1c Test: Clinical and Laboratory Value, Bulletin EP-11, Brea, CA: Beckman Instruments, Inc., 1991.

3. Christenson, R.H. Hemoglobin A1c . Chemistry and Clinical Use in Monitoring the Diabetic Patient, Brea, CA: Beckman Instruments, Inc., 1993.

4. Christenson, R.H., Francis, C.W., and Jesse, R.L. Myocardial infarction and unstable angina. (Poster) Clinical Chemistry News, July 1994.

5. Christenson, R.H. and Dougherty, R.J. The cardiac T assay for troponin T: The new tool for identifying minor myocardial damage. Produced by Boehringer Mannheim Corporation, Indianapolis, IN, 1994.

6. Christenson, R.H., Stubbs, P.J., Califf, R.M., Sachs, D.B., Gibler, W.B., Pepinne, C.J., and Ellis, A.K. Ischemic Heart Disease: Biochemical Markers in Risk and Outcomes Assessment. American College of Cardiology National Meeting, March 1995.

7. Christenson, R.H. and Collinson, P.O. Know What’s Coming: The Value of Cardiac Markers. American Association for Clinical Chemistry National Meeting, July 1995.

8. Christenson, R.H., Barish, R.A., Brogan, G.X., Lyston, D., Rodriquez, S., and Tucker, J.F. Clinical perspectives on chest pain: challenges in diagnosing the atypical patient. Video tape produced by Dade International, Miami, FL, 1995.

9. Christenson, R.H. Cardiac troponin T in the risk assessment of acute coronary syndromes. American Clinical Laboratory 1997; June issue: 4-7.

10. Christenson, R.H. Cardiac Troponin T: American Clinical Laboratory, 199811. Christenson, R.H. Markers of Bone Metabolism. Clinical Laboratory News, 199912. Christenson, R.H. Biochemical Markers and the Era of Troponin. Heart Attack: The Public Health

Challenge for the New Millennium, 200013. Christenson, R.H. Evidence Based Medicine: The Answer Lies in Asking the Right Question.

Clinical Laboratory News, January 2001, Pages 10-12.14. Christenson, R.H. Biochemical Markers and the Era of Troponin. Heart Attack: The Public Health

Challenge for the New Millennium,200415. Bahr, R., Christenson, R.H., Farin, H., Hand, M.M., and Long, J.: Prodromal symptoms of an acute

myocardial infarction: overview of the evidence. Heart Attack: The Public Health Challenge for the New Millennium, 2003

16. Azzazy, H.M.E. and Christenson, R.H.: Biochemical Markers for Assessing Bone Disease. Advance 2004

Books

1. Christenson, R.H., Johnson, L.J., and Gregory, L.C. (Eds.) A Review of Clinical Chemistry. NY: McGraw-Hill, 1999

2. Price, C.P. and Christenson, R.H. (Eds.) Evidence Based Laboratory Medicine: Principles and Practice, Washington, DC: AACC Press, 2003

3 Price, C.P. and Christenson, R.H. (Eds.) Evidence Based Laboratory Medicine: Principles, Practice and Oucomes, Washington, DC: AACC Press, 2007.

4. Christopher P. Price, Joanne Lozar Glenn, Robert H. Christenson Applying Evidence-Based Laboratory Medicine: A Step-By-Step

Guide. Washington, DC: AACC Press, 2009.

Chapters in Books

1. Silverman, L.M., Christenson, R.H., and Grant, G.H. Proteins and Amino Acids. In: Tietz, N.W. (Ed.), Textbook of Clinical Chemistry, Philadelphia, PA: W.B. Saunders Co., 1986, pp. 519-618.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 8

2. Grant, G.H., Silverman, L.M., and Christenson, R.H. Amino Acids and Proteins. In: Tietz, N.W. (Ed.), Fundamentals of Clinical Chemistry, 3rd Edition, Philadelphia, PA: W.B. Saunders Co., 1987, pp. 291-345.

3. Gubar, K., Silverman, L.M., and Christenson, R.H. Analysis of Proteins. In: Taylor, E.H. (Ed.), Clinical Chemistry, New York, NY: John Wiley & Sons, Inc., 1989, pp. 83-108.

4. Christenson, R.H. and Silverman, L.M. Analysis of Enzymes. In: Taylor, E.H. (Ed.), Clinical Chemistry, New York, NY: John Wiley & Sons, Inc., 1989, pp. 109-144.

5. Christenson, R.H. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. In: Dufour, D.R. and Rifai, N. (Eds.), Professional Practice in Clinical Chemistry: A Review. 2nd Edition, American Association for Clinical Chemistry, Washington, D.C., 1993, pp. 59-72.

6. Ohman, E.M. and Christenson, R.H. Noninvasive assessment of myocardial reperfusion and reocclusion. In: Topol, E.J. and Serruys, P.W. (Eds.), Current Review of Interventional Cardiology, Current Medicine, Philadelphia, PA: 1994; Chapter 6, pp. 6.1-6.15.

7. Christenson, R.H. and Silverman, L.M. Amino Acids and Proteins. In: Burtis, C.A. and Ashwood, E.R. (Eds.), Tietz Textbook of Clinical Chemistry, 2nd Edition, Philadelphia, PA: W.B. Saunders Co., 1994, pp. 625-734.

8. Dufour, D.R. and Christenson, R.H. (Eds.), Professional Practice in Clinical Chemistry: A Review, 3rd Edition, American Association for Clinical Chemistry, Washington, D.C., 1995

9. Christenson, R.H. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. In: Dufour, D.R. and Christenson, R.H. (Eds.), Professional Practice in Clinical Chemistry: A Review, 3rd Edition, American Association for Clinical Chemistry, Washington, D.C., 1995, pp. 62-74.

10. Christenson, R.H. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. In: Dufour, D.R. and Christenson, R.H. (Eds.), Professional Practice in Clinical Chemistry: A Review. 4th

Edition, American Association for Clinical Chemistry, Washington, D.C., 1995, pp. 70-82. 11. Christenson, R.H. and Silverman, L.M. Amino Acids and Proteins. In: Burtis, C.A. and Ashwood,

E.R. (Eds.), Tietz Fundamentals of Clinical Chemistry, 4th Edition. Philadelphia, PA: W.B. Saunders Co., 1996, pp. 240-282.

12. Christenson, R.H., Panigrahi, K., Chapman, J.C., and Silverman, L.M. Isoenzymes. In: Kaplan, L.A. and Pesce, A.J. (Eds.), Clinical Chemistry, Theory, Analysis, and Correlation. 3rd Edition, St. Louis, MO: C.V. Mosby Co., 1996, pp. 1077-1085.

13. Chapman, J.C., Christenson, R.H., and Silverman, L.M. Cardiac Disease and Hypertension. In: Kaplan, L.A. and Pesce, A.J. (Eds.), Clinical Chemistry, Theory, Analysis, and Correlations, 3rd Edition. St. Louis, MO: C.V. Mosby Co., 1996, pp. 593-612.

14. Christenson, R.H. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. In: Dufour, D.R. and Howanitz, P.J. (Eds.), Professional Practice in Clinical Chemistry: A Review. American Association for Clinical Chemistry, Washington, D.C., 1996, pp. 211-224.

15. Newby, L.K., Christenson, R.H., and Ohman, E.M.: Role of the troponins and other markers of myocardial necrosis and risk stratification. In: Topol, E.J. (Ed.), Acute Coronary Syndromes. NY: Marcel Dekker, Inc., 1997, pp.405-435.

16. Christenson, R.H. and Azzazy, H.M.E. Amino Acids. In: Burtis, C.A. and Ashwood, E.R. (Eds.), Tietz Textbook of Clinical Chemistry, 3rd Edition, Philadelphia, PA: W.B. Saunders Co., 1998, pp. 444-476.

17. Christenson, R.H. Point of Care Testing of Cardiac Markers. In: Wu, A.H.B. (Eds.), Markers for Cardiac Disease. Totowa, NJ: Humana Press, 1998.

18. Newby, L.K., Gibler, W.B., Christenson, R.H., and Ohman, E.M.: Serum markers for diagnosis and risk stratification in acute coronary syndromes. In: Cannon, C.P. (Ed.), Management of Acute Coronary Syndromes. Totowa, NJ: Humana Press, Inc., 1998, pp. 147-171.

19. Christenson, R.H. and Anderson, P.F. Separation Techniques. In: Dufour, D.R. (Ed.), Professional Practice in Clinical Chemistry: A Review. Pages 6-1 to 6-19. American Association for Clinical Chemistry, Washington, D.C., 1999.

20. Christenson, R.H. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. In: Dufour, D.R. (Ed.). Professional Practice in Clinical Chemistry: A Review. Pages 14-1 to 14-18. American Association for Clinical Chemistry, Washington, D.C., 1999.

21. Newby, K.N., Christenson, R.H., and Ohman, E.M. Biochemical Markers of Cardiac Injury. In: Cannon, C.P. (Ed.), Totowa, NJ: Humana Press, 1999.

22. Newby, L.K., Christenson, R.H.,and Ohman, E.M.: Role of the troponins and other markers of

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 9

myocardial necrosis and risk stratification. In: Topol, E.J. (Ed.), Acute Coronary Syndromes, 2nd Edition. Revised and Expanded. NY: Marcel Dekker, Inc., 2000, pp. 329-372.

23. Christenson, R.H. and Anderson, P.F.: Separation techniques. In: Christenson, R.H., Johnson, L.J., and Gregory, L.C. (Eds.). A Review of Clinical Chemistry. NY: McGraw-Hill, 2001, pp. 323-350.

24. Christenson, R.H. and Azzazy, H.M.E.: Amino acids. In: Burtis, C.A. and Ashwood, E.R. (Eds.). Fundamentals of Clinical Chemistry, 5th Edition. Philadelphia, PA: W.B. Saunders Co., 2001, pp. 300-324.

26. Newby, L.K., Gibler, W.B., Christenson, R.H., and Ohman, E.M.: Serum markers for diagnosis and risk stratification in acute coronary syndromes. In: Cannon, C.P. (Ed.), Management of Acute Coronary Syndromes, 2nd Edition. Totowa, NJ: Humana Press, Inc., 2002, pp. 183-210.

25. Christenson, R.H. and Azzazy, H.M.E.: Assessing reperfusion and prognostic infarct sizing with biochemical markers: Practice and promise. In: Wu, A.H.B. (Ed.), Markers for Cardiac Disease, 2nd Ed. Totowa, NJ: Human Press, 2003, pp. 59-86.

27. Sanhai, W.R. and Christenson, R.H. Isoenzymes and isoforms. In: Kaplan, L.A., Pesce, A.J., and Kazmierczak, S.C. (Eds.), Clinical Chemistry, Theory, Analysis, and Correlation, 4th Edition. St. Louis, MO: C.V. Mosby Co., 2003, pp. 1064-1072.

28. Sanhai, W.R. and Christenson, R.H. Cardiac disease and muscle disease. In: Kaplan, L.A., Pesce, A.J., and Kazmierczak, S.C. (Eds). Clinical Chemistry, Theory, Analysis, and Correlation, 4th Edition. St. Louis, MO: C.V. Mosby Co., 2003, pp. 566-579.

29. Christenson, R.H. and Azzazy, H.M.E. Point of C-are Testing of Cardiac Markers. In: Nichols, J.H. (Ed.), Point of Care Testing, Totowa, NJ: Humana Press, 2003, pp. 379-416.

30. Hassan M. E. Azzazy HME and Christenson RH. Evidence-Based Laboratory Medicine. In: Clarke W and Dufour DR. Contemporary Practice in Clinical Chemistry. In Press

31. Christenson RH and Azzazy HME. Biomarkers of Cardiac Necrosis: Past, Present and Future. In: Morrow DM. Cardiac Biomarkers in the Management of Cardiovascular Disease. In Press

32. Christenson RH. Proteins Analysis and Interpretation in Urine Serum and Cerebrospinal Fluid. In: Clarke W and Dufour DR. Contemporary Practice in Clinical Chemistry. Washington DC, AACC Press, 2006, pp

33. Christenson RH. Evidence Based Laboratory Medicine. In: Clarke W and Dufour DR. Contemporary Practice in Clinical Chemistry. Washington, DC, AACC Press, 2006, pp

34. Cardiac troponin: tomorrows marker. RH. Christenson. Biomarkers in Acute Coronary Syndroms DA Morrow editor (in press)

35. Cardiac troponin increases in conditions other than myocardial infarction. RH Kelly, WE Kelley, Cardiac Biomarkers in Modern Medicine: Practical Knowledge for the Clinician Biomarkers in Medicine. J Januzzi editor (in press)

36. Point of Care Testing in the Context of Acute Coronary Syndromes, Heart Failure, Stroke and Venous Thromboembolism: Is there Evidence of “A Need for Speed”? RH Christenson, PO Collinson, Point of Care, 3rd Edition, CP Price editor.

37. Cardiac Markers: A Chest Pain Center Focus, RH Christenson. Society of Chest Pain Centers and Providers on the Short Stay Management of Chest Pain WF Peacock, editor

38. Evidence-Based Laboratory Medicine, Kelley WE, Azzazy HME, Christenson RH. In: second edition of Contemporary Practice in Clinical Chemistry AACC Press, W Clarke, Editor.

39. Proteins: Analysis and Interpretation in Serum, Urine, and Cerebrospinal Fluid. Kelley WE, Azzazy HME, Christenson RH. In: second edition of Contemporary Practice in Clinical Chemistry AACC Press, W Clarke, Editor.

40. Sanhai, W.R. and Christenson, R.H. Cardiac disease and muscle disease. In: Kaplan, L.A., Pesce, A.J., and Kazmierczak, S.C. (Eds). Clinical Chemistry, Theory, Analysis, and Correlation, 4th Edition. St. Louis, MO: C.V. Mosby Co., 2003, pp. 566-579.

41. Sanhai, W.R. and Christenson, R.H. Cardiac disease and muscle disease. In: Kaplan, L.A., Pesce, A.J., and Kazmierczak, S.C. (Eds). Clinical Chemistry, Theory, Analysis, and Correlation, 5th Edition. St. Louis, MO: C.V. Mosby Co., 2010, pp. 566-579.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 10

Journal Articles (Peer-Reviewed)

1. Christenson, R.H., McGlothlin, C.D., Hedrick, R., and Cate, J.C. Simplified fluorometric assay for metanephrine and normetanephrine in urine. Clin Chem, 1982; 28:1204-1207.

2. Christenson, R.H., Hammond, J.E., Hull, J.H., and Bustrack, J.A. A routine method for the determination of digoxin in urine by radioimmunoassay. Clin Chem Acta, 1982; 120: 13-19.

3. Christenson, R.H. and McGlothlin, C.D. Elucidation of metanephrine to normetanephrine and epinephrine to norepinephrine ratios by fluorescence derivative spectroscopy. Anal Chem, 1982; 54:2015-2017.

4. Christenson, R.H., Behlmar, P., Howard, J.F., Winfield, J.B., and Silverman, L.M. Interpretation of cerebrospinal fluid protein assays in various neurologic diseases. Clin Chem, 1983; 29: 1028-1030.

5. Bustrack, J.A., Katz, J.D., Hull, J.H., Foster, J.R., Hammond, J.E., and Christenson, R.H. Bioavailability of digoxin capsules and tablets: Effects of coadministered fluid volume. J Pharm Sci, 1984; 73:1397-1403.

6. Christenson, R.H., Dent, G.A., and Tuszynski, A. Two radioassays for serum vitamin B12 and folate determination compared in a reference interval study. Clin Chem, 1985; 31:1358-1360.

7. Christenson, R.H., Tucker, J.A., and Allen, E. Results of dipstick tests, visual inspection, microscopic examination of urine sediment, and microbiological cultures of urine compared for simplifying urinalysis. Clin Chem, 1985; 31:448-451.

8. Christenson, R.H., Russell, M.E., Gubar, K.T., Silverman, L.M., and Ebers, G.C.: Oligoclonal banding in cerebrospinal fluid assessed by electrophoresis on agarose after centrifugal sample concentration through a microconcentrator membrane. Clin Chem, 1985; 31:1734-1736.

9. Bjornsson, T.D., Huang, A.T., Roth, P., Jacob, D.S., and Christenson, R.H. Effects of high-dose cancer chemotherapy on the absorption of digoxin after two different formulations. Clin Pharmacol Ther, 1986; 39:25-28.

10. Toffaletti, J., Christenson, R.H., Mullins, S., and Harris, R.E. Relationship between serum lactate and ionized calcium in open-heart surgery. Clin Chem. 1986; 32:1849-1853.

11. Christenson, R.H., Scroggs, M.W., and Odom, J.D. Increased lactate dehydrogenase isoenzyme 1 in serum and tumor tissue of a patient with small-cell carcinoma. Clin Chem 1986;32:1234-1236.

12. Rifai, N., Christenson, R.H., Gelman, B.B., and Silverman, L.M. Automated determination of apolipoprotein A1 and apolipoprotein E in cerebrospinal fluid. Clin Chem 1986; 32:2207 (Technical Brief).

13. Christenson, R.H., Studenberg, S.D., Beck-Davis, S., and Sedor, F.A. Digoxin-like immunoreactivity eliminated from serum by centrifugal ultrafiltration before fluorescence polarization immunoassay of digoxin. Clin Chem, 1987; 33:606-608.

14. Rifai, N., Christenson, R.H., Gelman, B.B., and Silverman, L.M. Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Clin Chem 1987; 33:1155-1158.

15. Albright, R.E., Christenson, R.H., Schold, S.C., Schneider, K.A., Habig, R.L., Johnston, W.W., Pickett, M.P., Kulik, W.F., and Mears, T.P. Establishment of a cerebrospinal fluid bank. Neurology 1988; 38: 492-494.

16. Gelman, B.B., Rifai, N., Christenson, R.H., and Silverman, L.M. Cerebrospinal fluid and plasma apolipoproteins with multiple sclerosis. Ann Clin Lab Sci 1988; 18:46-59.

17. Albright, R.E., Christenson, R.H., Habig, R.L., Mears, T.R., and Schneider, K.A. Cerebrospinal fluid (CSF) TRAP: a method to improve laboratory efficiency. Am J Clin Pathol 1988; 90:707-710.

18. Christenson, R.H., Hassett, B.J., and Albright, R.E. Lyphilizing effects upon cerebrospinal fluid stored at –70oC. Clin Chem 1988; 34:2585. (Technical Brief)

19. Christenson, R.H. Digoxin-like immunoreactive factors. Clinical Chemistry News 1988; 14(9):10-11.20. Christenson, R.H., Findley, P.R., and Silverman, L.M. Immunochemical assays for IgG, IgA, IgM and transferrin

compared. Clin Biochem. 1989; 22:271-276. 21. Albright, R.E., Christenson, R.H., Bledsoe, M.C., Wilkins, R.H., and Djang, W.T. CSF TRAP: a procedure to

improve laboratory testing with myelography. Neurosurgery 1989; 25:76-80.22. Christenson, R.H., Ohman, E.M., Clemmenson, P., Grande, P., Toffaletti, J., Silverman, L.M., Vollmer, R.T., and

Wagner, G.S. Characteristics of creatine kinase-MB and MB isoforms in serum after reperfusion in acute myocardial infarction. Clin Chem. 1989; 35:2179-2185.

23. Christenson, R.H., Russell, M.E., and Hassett, B.J. Cerebrospinal fluid: electrophoresis and methods for determining immunoglobulin G compared. Clin Biochem. 1989; 22:429-432.

24. Albright, R.E., Christenson, R.H., Habig, R.L., Mears, T.P., and Schneider, K.A. Procedura TRAP per l’esme del liquido cerebrospinale (CSF). Am J Clin Pathol Ed It Giugno 1989; 2: 243-247.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 11

25. Albright, R.E., Christenson, R.H., Babb, J.D., Sparks, E.W., Butts, R.K., Hassett, B.J., Bledsoe, M.C., Graham, C.B., Emlet, J.L., and Smith, M.P. Management of cerebrospinal fluid. NCMJ 1990; 51:72-76.

26. Sachs, C.W., Christenson, R.H., Pratt, P.C., and Lynn, W.S. Neutrophil elastase activity and superoxide production are diminished in alcoholics. Am Rev Respir Dis 1990; 141:1249-1255.

27. Christenson, R.H., Ohman, E.M., Clemmensen, P., Toffaletti, J., Silverman, L.M., Vollmer, R.T., and Wagner, G.S. Relative increase in creatine kinase MB isoenzyme during reperfusion after myocardial infarction is method dependent. Clin Chem 1990; 36:1444-1449.

28. Albright, R.E., Christenson, R.H., Emlet, J.L., Graham, C.B., Bledsoe, M.C., Estevez, E.G., Wilson, M.L., Reller, L.B., and Schneider, K.A. Issues in cerebrospinal fluid management: CSF venereal disease research laboratory testing. Am J Clin Pathol 1991; 95:397-401.

29. Albright, R.E., Graham, C.B., Christenson, R.H., Schell, W.A., Bledsoe, M.C., Emlet, J.L., Meers, T.P., Reller, L.B., and Schneider, K.A. Issues in cerebrospinal fluid testing: Acid-fast bacillus smear and culture. Am J Clin Pathol 1991; 95:418-423.

30. Madden, J.F. and Christenson, R.H. Clinical use of the MM and MB isoforms of creatine kinase. Clinical Chemistry News 1991; 17(6): 15.

31. Currie, M.S., Simel, D.L., Christenson, R.H., Holmes, C., Crawford, J., Cohen, H.J., and Rao, K.M.K. Antiinflammatory effects of pentoxifylline in claudication. Am J Med Sci 1991; 301(2):85-90.

32. Christenson, R.H., Ohman, E.M., Vollmer, R.T., Clemmenson, P., Grande, P., and Wagner, G.S. Serum release of the creatine kinase tissue-specific isoforms MM3 and MB2 is simultaneous after myocardial reperfusion. Clin Chem Acta 1991; 200:23-33.

33. Christenson, R.H., Roeback, J.R., Watson, T.E., and Hla, K.M. Improving the reliability of total and high-density lipoprotein cholesterol measurement: four strategies compared in a high-risk population. Arch Pathol Lab Med 1991; 115:1212-1216.

34. Albers, J.J., Marcovina, S.M., and Christenson, R.H. Lecitin cholesterol acyltransferase in human cerebrospinal fluid: reduced level in patients with multiple sclerosis and evidence of direct synthesis in the brain. Int J Clin Lab Res 1992; 22:169-172.

35. Christenson, R.H. Diabetes Mellitus. Clinical Chemistry News 1992; 18:10-11.36. Christenson, R.H. Specificity of an immunochemical reagent for quantifying the isoforms of creatine kinase-MB. J

Clin Lab Anal 1993; 7:220-224.37. Ohman, E.M., Christenson, R.H., Clemmensen, P., and Wagner, G.S. Myocardial salvage after reperfusion:

observations from analysis of serial electrodardiographic and biochemical indices. J Electro 1993; 25:10-14.38. Vollmer, R.T., Christenson, R.H., Reimer, K., and Ohman, E.M. The log-normal function is ideal for analysis of

serum markers of tissue necrosis. Am J Clin Pathol 1993; 100:293-298.39. Ohman, E.M., Christenson, R.H., Califf, R.M., George, B.S., Samaha, J.K., Kereiakes, D.J., Worley, S.J., Wall, T.C.,

Berrios, E., Sigmon, K.N., Lee, K., and Topol, E.J. Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. Am Heart J 1993; 126:819-826.

40. Baskin, J., Wilkins, M.L., Ohman, E.M., Clemmensen, P., Grande, P., Christenson, R.H., Sevila, D.C., Wagner, N.B., and Wagner, G.S. Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. AJC 1993; 71:1362-1365.

41. Panigrahi, K., Fisher, R., Reiss, O., Kress, B., Misrahi, I., and Christenson, R.H. Measurement of skeletal alkaline phosphatase: analytical performance and clinical usefulness. Clin Chem 1993; 40:822-828.

42. Gregory, L.C., Duh, S.H., and Christenson, R.H. Evaluation of eight compact analysis systems for measuring total cholesterol. Clin Chem 1994; 40:579-585.

43. Christenson, R.H., Ohman, E.M., Topol, E.J., O’Hanesian, M.A., Sigmon, K.N., Duh, S.H., Kereiakes, D., Worley, S.J., Georges, B.S., Pizzo, C.K., Wall, T.C., and Califf, R.M. Creatine kinase MM and MB isoforms after thrombolytic therapy and acute angiography. Clin Chem 1995; 41:844-852.

44. Christenson, R.H., Duh, S.H., Clarisse, D.E., and Zorn, N. Thyroid function testing evaluated on three immunoassay systems. J Clin Lab Anal 1995; 9:178-183.

45. Newby, L.K., Gibler, W.B., Ohman, E.M., and Christenson, R.H. Biochemical markers in suspected acute myocardial infarction. The need for early assessment. Clin Chem 1995; 41:1263-1265.

46. Sprung, J., Mackenzie, C.F., Barnas, G.M., Williams, J.E., Parr, M., Christenson, R.H., Hoff, B.H., Sakamoto, R., and Kramer, A. Oxygen transport and cardiovascular effects of resuscitation from severe hemorrhagic shock using hemoglobin solutions. Crit Care Med 1995; 23:1540-1553.

47. Eldridge, J., Russell, R., Christenson, R.H., Sakomoto, R., Williams, J., Parr, M., Trump, B.F., and Mackenzie, C.F. Liver function and morphology following resuscitation from severe hemorrhagic shock with hemoglobin solutions or

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 12

autologous blood. Crit Care Med 1996; 24:663-671.48. Alonsozana, G.L. and Christenson, R.H. The case for troponin T: marker for effective risk stratification of patients

with acute cardiac ischemia. Clin Chem 1996; 42:803-808.49. Gurbel, P.A., Navetta, F.I., Bates, E.R., Muller, D.W., Tenaglia, A.N., Miller, M.J., Muhlstein, B., Mermiller, J.B.,

Davidson, C.J., Aguirre, F.V., Beauman, G.J., Berdan, L.G., Leimberger, J.D., Bovil, E.G., Christenson, R.H., and Ohman, E.M. Lesion-directed administration of ateplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Cath Cardio Diag 1996; 37:382-391.

50. Ohman, E.M., Armstrong, P.W., Christenson, R.H., Granger, C.B., Katus, H., Hamm, C.W., O’Hanesian, M.A., Lee, K.L., Wagner, G.S., Califf, R.M., and Topol, E.J. for the GUSTO-IIa investigators. Risk stratification with admission cardiac troponin T levels in acute myocardial ischemia. N Engl J Med 1996; 335:1333-41.

51. Jurlander, B., Clemmenson, P., Ohman, E.M., Christenson, R.H., Wagner, G.S., and Grande, P. Serum myoglobin for early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction. Eur Heart J 1996; 17:399-406.

52. Christenson, R.H., Ohman, E.M., Topol, E.J., O’Hanesian, M.A., Sigmon, K.N., Duh, S.H., Kereiakes, D., Worley, S.J., George, B.S., Alonsozana, Wall, T.C., and Califf, R.M. Combining myoglobin, creatine kinase-MB and clinical variables for assessing coronary reperfusion after thrombolytic therapy. Circulation 1997; 96:1776-1782.

53. Christenson, R.H., Fitzgerald, R.L., Ochs, L., Rozenberg, M., Frankel, W.L., David, A., Herold, D.A., Duh, S.H., Alonsozana, G.L., and Jacobs, E. Characteristics of a 20-minute whole blood rapid assay for cardiac troponin T. Clin Biochem 1997; 30:27-33.

54. Azzazy, H.M.E., Duh, S.H., Maturen, A., Schaller, E., Shaw, L., Grimaldi, R., Schock, G., and Christenson, R.H. Multicenter study of the abbott non-pretreatment axsym digoxin II assay: comparison on the susceptibility of seven methods to digoxin-like immunoreactive factors. Clin Chem 1997; 43:1635-1640.

55. Alonsozana, G.L.G., Elfath, M.D., MacKenzie, C.F., Gregory, L.C., Duh, S.H., Trump, B.F., and Christenson, R.H. In vitro interference of the rec cell substitute pyridoxalated hemoglobin-polyoxyethylene (PHP88) with blood compatibility, coagulation, and clinical chemistry testing. J Cardio Vas Anes 1997; 11:840-845.

56. Christenson, R.H. Biochemical markers of bone metabolism: An overview. Clin Biochem 1997; 30:573-593.57. Christenson, R.H., Newby, L.K., and Ohman, E.M. Cardiac markers in the assessment of acute coronary syndromes.

Md Med J 1997; 46(10): 18-24 (Suppl.).58. Jones, J., Kinnel, M., Christenson, R.H., and Reimschuessel, R. Gentamicin blood levels in toadfish and goldfish. J

Aquatic Animal Health 1997; 9:211-215.59. Newby, L.K., Christenson, R.H., and Ohman, E.M. The role of enzymatic markers in the new millennium: point-of-

care testing and beyond. J Thromb Thrombolysis 1998:5:S107-S112.60. Azzazy, H.M.E., Chou, P.P., Poklis, A., Schock, G., and Christenson, R.H. Multicenter evaluation of the abbott

axsym procainamide and N-acetylprocainamide assays: Comparison with abbott tdx/tdxflx, syva emit 2000, dupont aca, and HPLC methods. Clin Biochem 1998;31:55-58.

61. Christenson, R.H., Apple, F.S., Morgan, D.L., Alonsozana, G.L., Mascotti, K., Olson, M., McCormack, R.T., Wains, F.H., Keffer, J.H., and Duh, S.H. Cardiac troponin I measurement on the ACCESS immunoassay system: analytical and clinical performance characteristics. Clin Chem 1998; 44:52-60.

62. Christenson, R.H., Newby, L.K., Ohman, E.M., Califf, R.M., Armstrong, P.W., Granger, C.B., Peck, S., Duh, S.H., Katus, H.A., and Topol, E.J. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. Clin Chem 1998; 44:487-94.

63. Newby, L.K., Christenson, R.H., Ohman, E.M., Armstrong, P.W., Wildeman, N., Lee, K., Hamm, C.W., Katus, H.A., Cianciolo, C., Granger, C.B., Topol, E.J., and Califf, R.M. The value of serial troponin T measurements for risk stratification in patients with acute coronary syndromes. Circulation 1998; 98:1853-1859.

64. Christenson, R.H. and Azzazy, H.M.E. Biochemical markers of the acute coronary syndrome. Clin Chem 1998; 44: 1855-64.

65. Broyles, D.L., Neilsen, R.G., Bussett, E.M., Lu, W.D., Mizrahi, I.A., Nunnelly, P.A., Ngo, T.A., Noell, J., Christenson, R.H., and Kress, B.C. Characteristics of tandem-MP ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 1998; 44:2139-2947.

66. Azzazy, H.M.E., Cummings, P.J., Ambrozak, D.R., and Christenson, R.H. Production and characterization of monoclonal antibodies to human carbonic anhydrase III. Hybridoma 1998; 17:553-558.

67. Apple, F.S., Christenson, R.H., Valdes, R., Andriak, A.J., Berg, A., Duh, S.H., Feng, Y.J., Jortani, S.A., Johnson, N.A., Koplen, B., Mascotti, K., and Wu, A.H.B. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1998; 45:199-206.

68. Robinson, D. and Christenson, R.H. Creatine kinase and its CK-MB isoenzyme: The conventional marker for the

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 13

diagnosis of myocardial infarction. J Emer Med 1999; 17(1):95-104.69. Christenson, R.H., Apple, F.A., Bauer, R.S., Jacob, A., Landt, Y., Magneson, G., Vaidya, H., Wu, A.H.B., and

Azzazy, H.M.E. Standardization of CK-MB mass assays: the use of recombinant CK-MB as a reference material. Clin Chem 1999; 45:1414-1423.

70. Azzazy, H.M.E., Duh, S.H., Fitzgerald, R.L., McLawhon, R.L., Rosenthal, M., and Christenson, R.H. Multisite study of the second generation whole blood rapid assay for cardiac troponin T. Ann Clin Biochem 1999; 36:438-446.

71. Christenson, R.H., Demers, L.M., Goldsmith, B.M., Noel, S.A., and Duh, S.H. Performance characteristics of the creatine kinase-MB mass assay on the Vitros Eci analyzer. Clin Biochem 1999; 32:237-240.

72. Apple, F.S., Maturen, R.E., Mullins, R.E., Painter, P.C., Pessin-Minsley, M.S., Webster, R.A., Flores, J.S., DeCresce, R., Fink, D.J., Buckley, P.M., Marsh, J., Ricchluti, V., and Christenson, R.H. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999; 45:199-206.

73. Christenson, R.H. and Duh, S.H. Evidence based approach to practice guides and decision thresholds for cardiac markers. Scand J Clin Lab Invest 1999; 59 (Suppl 230):90-102.

74. Panteghini, M., Apple, F.S., Christenson, R.H., Dati, F., Mair, J., and Wu, A.H.B. Recommendations on the use of biochemical markers of cardiac assays. Scand J Clin Lab Invest 1999; 59 (Suppl 230): 103-112.

75. Dati, F., Panteghini, M., Apple, F.S., Christenson, R.H., and Mair, J. Strategies and concepts on standardization of cardiac marker assays. Scand J Clin Lab Invest 1999; 59 (Suppl 230): 113-123.

76. Robinson, D.J. and Christenson, R.H. Creatine kinase and its CK-MB isoenzyme. The conventional marker for the diagnosis of acute myocardial infarction. J Emer Med 1999; 17(1):95-104.

77. Hudson, M.P. , Christenson, R.H., Newby, L.K., Kaplan, A.L., and Ohman, E.M. Cardiac markers: Point of care testing. Clin Chim Acta 1999; 284(2):223-37.

78. Christenson, R.H. Overview of biochemical markers of the acute coronary syndromes: Present and future. MLO 1999; 31(9):26-41.

79. Christenson, R.H., Vollmer, R.T., Ohman, E.M., Peck, S., Thompson, T., Duh, S.H., Ellis, S.G., Newby, K., Topol, E.J., and Califf, R.M. Relation of temporal creatine kinase-MB and clinical outcome after thrombolytic therapy. Am J Cardiol 2000; 85:543-547.

80. Bahr, R.D., Leino, E.V., and Christenson, R.H.: Prodromal unstable anginal in acute myocardial infarction: Pronostic value of short-term and long-term outcome and predictor of infarct size. Am Heart J 2000; 140:126-33.

81. Beuerle, J.R., Azzazy, H.M.E., Styba, G., Duh, S.H., and Christenson, R.H. Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients. Clin Chim Acta 2000; 294:115-128.

82. Beuerle, J.R., Azzazy, H.M.E., Apple, F.S., Duh, S.H., Tan, A., and Christenson, R.H. Performance characteristics of a new myoglobin microparticle enzyme immunoassay: A multicenter evaluation. Clin Biochem 2000; 33:595-598.

83. Nair, G.V., Gurbel, P.A., Fuzaylov, S.Y., Davis, C.J., Ohman, E.M., Bahr, R.D., Christenson, R.H., and Serebruany, V.L. Combining necrosis and platelet markers for perfecting myocardial infarction rule out: How close are we? Cardiology 2000; 93:50-55.

84. Roe, M.T., Ohman, E.M., Maas, A.C.P., Christenson, R.H., Mahaffey, K.W., Granger, C.B., Harrington, R.A., Califf, R.M., and Krucoff, K.W. Shifting the open artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 2001 Jan; 37(1):9-18.

85. Apple, F.S., Murakami, M., Panteghini, M., Christenson, R.H., Data, F., Mair, J., and Wu, A.H. International survey on the use of cardiac markers. Clin Chem 2001; 47:587-588.

86. Christenson, R.H., Duh, S.H., Sanhai, W.R., Wu, A.H.B., Holtman, V., Painter, P., Branham, E., Apple, F.S., Murakami, M.A., and Morris, D.L. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem, 2001; 47:464-470.

87. Christenson, R.H., Duh, S.H., Apple, F.S., Bodor, G.S., Bunk, D.M., Dalluge, J., Panteghini, M., Potter, J.D., Welch, M.J., Wu, A.H.B., and Kahn, S.E. Standardization of cardiac Troponin I assays: Round robin of ten candidate reference materials. Clin Chem, 2001; 47:431-437.

88. Newby, L.K., Ohman, E.M., Christenson, R.H., Moliterno, D.J., Harrington, R.A., White, H.D., Armstrong, P.W., Van de Werf, F., Pfisterer, M., Hasselblad, V., Califf, R.M., and Topol, E.J. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The PARAGON-B troponin T substudy. Circulation, 2001; 103:2891-2896

89. Christenson, R.H., Duh, S.H., Roe, M.T., and Ohman, E.M.: Modeling biochemical marker release: Inclusion of the Falloff Constant (Kf) for determining outcomes and discriminating therapies. Cardio Tox, 2001; 1: 171-176

90. Wu, A.H.B., Morris, D.L., Fletcher, D.R., Apple, F.S., Christenson, R.H., and Painter, P.C. Analysis of the albumin

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 14

cobalt binding test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardio Tox, 2001; 1: 141-146

91. Bahr, R.D., Christenson, R.H., Farin, H., Hand, M.M., and Long, J.M. Prodromal symptoms of acute myocardial infarction: Overview of evidence. Md Med, 2001; Spring; Suppl: 49-59

92. Christenson, R.H. Biochemical markers and the era of troponin. Md Med, 2001; Spring; Suppl: 98-10393. Sanhai, W.R., Romero, L.F., Hickey, G., Ruttle, D., and Christenson, R.H. Performance characteristics of a revised

cardiac troponin I assay for the opusTM plus immunoassay system. Clin Biochem, 2001; 34: 579-82.94. Nuwayhid, I., McPhaul, K., Bu-Khuzam, R., Duh, S.H., Christenson, R.H., and Keogh, J.P. Determinants of elevated

blood lead levels among working men in Greater Beirut. J Med Liban, 2001; 49(3): 132-9.95. LeBeau, M.A., Christenson, R.H., Levine, B., Darwin, W.D., and Huestis, M.A. Intra- and interindividual variations

in urinary concentrations of endogenous gamma-hydroxybutyrate.J Anal Toxicol, 2002; 26(6): 340-6.

96. Cantor, W.J., Newby, L.K., Christenson, R.H., Tuttle, R.H., Hasselblad, V., Armstrong, P.W., Moliterno, D.J., Califf, R.M., Topol, E.J., and Ohman, E.M. Prognostic significance of elevated troponin-I after percutaneous coronary intervention. J Am Coll Cardiol, 2002; 39(11): 1738-44.

97. Azzazy, H.M.E. and Christenson, R.H. Cardiac markers of acute coronary syndromes: Is there a case for point-of-care testing? Clin Biochem, 2002;35(1)13-27.

98. Wieczorek, S.J., Wu, A.H.B., Christenson, R.H., Krishnaswamy, P., Gottlieb, S., Rosano, T., Hager, D., Gardetto, N., Chiu, A., Bailly, K.R., and Maisel, A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure-a multi-center evaluation. Am Heart J, 2002;144(5):834-9.

99. Bahr, R.D., Gurbel, P.A., Malinin, A.I., Wentz, C., Christenson, R.H., Roe, M.T., Gibler, W.B., Kitt, M.M., Ohman, E.M., and Serebruany, V.L. Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol, 2002;90(3):310-2.

100. Cannon, C.P., Hand, M.H., Bahr, R., Boden, W.E., Christenson, R., Gibler, W.B., Eagle, K., Lambrew, C.T., Lee, T.H., MacLeod, B., Ornato, J.P., Selker, H.P., Steele, P., and Zalenski, R.J. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J, 2002; 143: 777-89.

101. Hoekstra, J.W., Pollack, C.V., Roe, M.T., Peterson, E.D., Brindis, R., Harrington, R.A., Christenson, R.H., Smith, S.C., Ohman, E.M., and Gibler, W.B. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the crusade initiative. Acad Emerg Med, 2002; 9: 1146-1155.

102. Fink, J.C., Onuigbo, M.A., Blahut, S.A., Christenson, R.H., Mann, D., Bartlett, S.T., and Weir, M.R.: Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: A pilot case-control study. Am J Kidney Dis, 2002 May; 39:1096-1101.

103. Gurbel, P.A., Galbut, B., Bliden, K.P., Bahr, R.D., Roe, M.T., Serebruany, V.L., Gibler, W.B., Christenson, R.H., Ohman, E.M.; EARLY Platelet Substudy. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration—therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis, 2002 Dec; 14(3):213-9.

104. Christenson, R.H., Mandichak, J.J., Duh, S.H., Augustyn, J.M., and Thompson, J.C. Clinical performance characteristics of a new photometric lithium assay: a multicenter study. Clin Chim Acta, 2003 Jan; 327: 157-164.

105. Kaul, P., Newby, L.K., Fu, Y., Hasselblad, V., Mahaffey, K.W., Christenson, R.H., Harrington, R.A., Ohman, E.M., Topol, E.J., Califf, R.M., Van de Werf, F., Armstrong, P.W., PARAGON-B Investigators. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol, 2003 Feb; 41(3): 371-80.

106. Phillips, J.W., Samady, H., Snyder, L., Christenson, R.H., Gibson, J., Bruns, D.E., Sayre, S., Gimple, L.W., Ragosta, M., Powers, E.R., Sarembock, I.J. Troponin I elevation following percutaneous coronary intervention does not predict future adverse outcomes. J Am Coll Cardiol, 2003 Mar 19; 41 (6 SupplB):532.

107. Roe, M.T., Peterson, E.D., Li, Y., Harrington, R.A., Pollack, C.V., Brindis, R.G., Christenson, R.H., Smith, S.C., Gibler, B., Magnus, O.E., Suboptimal adherence to the ACC/AHA non-ST elevation acute coronary syndrome practice guidelines for patients with positive troponin levels. J Am Coll Cardiol, 2003 Mar 19; 41 (6 Suppl B): 390.

108. deFillippi, C., Yoon, S., Bounds, C., Romar, L., Ro, A., Herzog, W., Stafford, L., Christenson, R.H. Early detection of myocardial ischemia by a novel blood-based biomarker: The kinetics of ischemia modified albumin. J Am Coll Cardiol, 2003 Mar 19; 41 (6 Suppl B): 340-1.

109. Rao, S.V., Ohman, E.M., Granger, C.B., Armstrong, P.W., Gibler, W.B., Christenson, R.H., Hasselblad, V., Stebbins, A., McNulty, S., and Newby, L.K. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol, 2003 Apr 15; 91(8):936-40.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 15

110. deFilippi, C., Wasserman, S., Rosanio, S., Tiblier, E., Sperger, H., Tocchi, M., Christenson, R., Uretsky, B., Smiley, M., Gold, J., Muniz, H., Badalamenti, J., Herzog, C., and Henrich, W. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA, 2003, 290(3): 353-9.

111. Vollmer, R.T., Govindan, R., Grziano, S.L., Gamble, G., Garst, J., Kelley, M.J., Christenson, R.H. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: An early measure of response. Clin Cancer Res, 2003 May; 9(5):1728-33.

112. Christenson, R.H., Leino, E.V., Giugliano, R.P., d Bahr, R.D. Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). Am J Cardiol, 2003 Sep 1;92(5):598-600.

113. Kandzari, D.E., Labinaz, M., Cantor, W.J., Madan, M., Gallup, D.S., Hasselblad, V., Joseph, D., Allen, A., Green, C., Hidinger, K.G., Krucoff, M.W., Christenson, R.H., Harrington, R.A., Tcheng, J.E. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to eliminate necrosis and damage trial). Am J Cardiol, 2003 Sep 15; 92(6):660-4.

114. Roe, M.T., Ohman, E.M., Pollack, C.V., Peterson, E.D., Brindis, R.G., Harrington, R.A., Christenson, R.H., Smith, S.C., Califf, R.M., and Gibler, W.B. Changing the model of care for patients with acute coronary syndromes – implementing practice guidelines and altering physician behavior. AHJ, 2003, Oct; 146(4):605-12.

115. Azzazy, H.M., Christenson, R.H. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev. 2003 Oct; 8(4): 315-20.

116. Azzazy, H.M., Romero, L.F., Hall, L., Ruttle, D., Christenson, R.H. Two-center clinical evaluation of a new automated fluorometric immunoassay for the quantitative analysis of total betaeta-human chorionic gonadotropin. Clin Biochem. 2003 Oct; 36(7):523-8.

117. Luepker, R.V., Apple, F.S., Christenson, R.H., Crow, R.S., Fortmann, S.P., Goff, D., Goldberg, R.J., Hand, M.M., Jaffe, A.S., Julian, D.G., Levy, D., Manolio, T., Mendis, S., Mensah, G., Pajak, A., Prineas, R.J., Reddy, K.S., Roger, V.L., Rosamond, W.D., Shahar, E., Sharrett, A.R., Sorlie, P., Tunstall-Pedoe, H.; AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers of Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation, 2003 Nov 18; 108(20): 2543-9.

118. Yeo, K.T., Wu, A.H., Apple, F.S., Kroll, M.H., Christenson, R.H., Lewandrowski, K.B., Sedor, F.A., Butch, A.W. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003 Dec; 338 (1-2):107-15.

119. Roe, M.T., Christenson, R.H., Ohman, E.M., Yang, H., Fraulo, E.S., Bahr, R., Fesmire, F.M., Storrow, A., Mollod, M., Peacock, W.F., Rosenblatt, J.A., Hoekstra, J.A., and Gibler, W.B.: A randomized, placebo-controlled trial of early use of eptifibatide for patients with non-ST-segment elevation acute coronary syndromes in the emergency department: the Eptifibatide for acute coronary syndromes–rapid versus late administration for therapeutic yield (EARLY) pilot trial. Am Heart J, 2003 Dec; 146:993-8.

120. Azzazy, H.M.E. and Christenson, R.H.: CK-MB and troponins: A clinically focused update. J Clin Ligand Assay, 2003; 25:132-149.

121.Cantor WJ, Vandenbroucke A, Strauss BH, Chisholm RJ, Young K, Christenson RH, Goldman L, Fitchett D. Do glycoprotein IIb/IIIa inhibitors interact with assays for myocardial necrosis? Clin Biochem. 2003;36:663-6.

122. Kandzari, D.E., Chu, A., Brodie, B.R., Stuckey, T.A., Hermiller, J.B., Vetrovec, G.W., Hannan, K.L., Krucoff, M.W., Christenson, R.H., Gibbons, R.J., Sigmon, K.N., Garg, J., Hasselblad, V., Collins, K., Harrington, R.A., Berger, P.B., Chronos, N.A., Hochman, J.S., and Califf, R.M.: Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol, 2004;93:636-9.

123. Apple, F.S., Murakami, M.M., Christenson, R.H., Campbell, J.L., Miller, C.J., Hock, K.G., and Scott, M.G.: Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta, 2004 345:123-7.

124. Panteghini, M., Linsinger, T., Wu, A.H., Dati, F., Apple, F.S., Christenson, R.H., Mair, J., and Schimmel, H.: Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials. Clin Chim Acta 2004; 341:65-72.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 16

125. Wu, A.H., Smith, A., Christenson, R.H., Murakami, M.M., and Apple, F.S.: Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin Chim Acta 2004; 346:211-9.

126. Fesmire, F.M., Christenson, R.H., Fody, E.P., and Feintuch, T.A.: Delta CK-MB outperforms myoglobin at 2 hours during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes. Ann Emerg Med, 2004 Jul; 44(1):12-9.

127. Christenson, R.H., Cervelli, D.R., Bauer, R.S., and Gordon, M.: Stratus ( R ) CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clin Biochem, 2004 Aug; 37(8):679-83.

128. Ohman EM, Roe MT, Smith SC Jr, Brindis RG, Christenson RH, Harrington RA, Gibler WB, Peterson ED. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004;148(5 Suppl):S34-9.

129. Panteghini, M., Pagani, F., Yeo, K.T., Apple, F.S., Christenson, R.H., Dati, F., Mair, J., Ravkilde, J., and Wu, A.H.: Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem, 2004; Feb; 50(2): 327-32.

130. Roe MT, Peterson ED, Pollack CV, Newby LK, Li Y, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk JD, Smith SC, Ohman EM, Gibler WB. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies and interventions for patients with non–ST-segment elevation acute coronary syndromes. Ann Emerg Med 2005;45:355-62.

131. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005;51:810-24.

132. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, Jaffe AS. Quality specifications for B-type natriuretic peptide assays. Clin Chem. 2005;51:486-93.

133. Christenson RH, deFilippi CP, Kreutzer D. Biomarkers of ischemia in patients with known coronary artery disease: do interleukin-6 and tissue factor measurements during dobutamine stress echocardiography give additional insight? Circulation. 2005;112:3215-7.

134. Azzazy HM, Mansour MM, Christenson RH. Doping in the recombinant era: strategies and counterstrategies. Clin Biochem. 2005;38:959-65

135. Roe MT, Peterson ED, Li Y, Pollack CV Jr, Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, Gibler WB, Ohman EM. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2005;165:1870-6.

136. Turer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, Ohman EM. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005;6:12.

137. deFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46:35-44.

138. Apple FS, Parvin CA, Buechler KF, Christenson RH, Wu AH, Jaffe AS. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005;51:2198-200.

139. Kupchak P, Wu AH, Ghani F, Newby LK, Ohman EM, Christenson RH. Influence of Imprecision on ROC Curve Analysis for Cardiac Markers. Clin Chem Clin Chem. 2006;52:752-3.

140. Newby LK, Roe MT, Chen AY, Ohman EM, Christenson RH, Pollack CV Jr, Hoekstra JW, Peacock WF, Harrington RA, Jesse RL, Gibler WB, Peterson ED; CRUSADE Investigators. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol 2006;47:312-8.

141. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem. 2006;52:19-29.

142. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, Lee A, Connerney I, Avari T, Christenson R, Tandry U, Griffith BP. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104-10.

1143. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic Peptide and B-type natriuretic Peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006;97:1530-4.

1144. Christenson RH, Tang WH. Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements. MedGenMed 2006:3;8:62.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 17

1145. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006;152:253-62.

1146. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Panteghini M, Welch MJ, Wu AH, Kahn SE. Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem 2006;52:1685-92.

1147. Roe MT, Peterson ED, Newby LK, Chen AY, Pollack CV Jr, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Braunwald E, Gibler WB, Ohman EM. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2006;151:1205-13.

1148. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006;152:1071-6.

1149. Nichols JH, Christenson RH, Clarke W, Gronowski A, Hammett-Stabler CA, Jacobs E, Kazmierczak S, Lewandrowski K, Price C, Sacks DB, Sautter RL, Shipp G, Sokoll L, Watson ID, Winter W, Zucker ML. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta 2007;379:14-28.

1150. SSherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167:367-73.

151. Christenson, R.H., Cervelli, D.R., Bauer, R.S., and Gordon, M: Stratus ( R ) CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clin Biochem, 2004 Aug; 37(8):679-83.

152. Ohman EM, Roe MT, Smith SC Jr, Brindis RG, Christenson RH, Harrington RA, Gibler WB, Peterson ED. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004;148(5) Suppl):S34-9.

153. Panteghini, M., Pagani, F., Yeo, K.T., Apple, F.S., Christenson, R.H., Dati, F., Mair, J., Ravkilde, J., and Wu, A.H.: Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem, 2004; Feb; 50(2): 327-32.

154. Roe MT, Peterson ED, Pollack CV, Newby LK, Li Y, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk JD, Smith SC, Ohman EM, Gibler WB. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies and interventions for patients with non–ST-segment elevation acute coronary syndromes. Ann Emerg Med 2005;45:355-62.

155. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005;51:810-24.

156. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, Jaffe AS. Quality specifications for B-type natriuretic peptide assays. Clin Chem. 2005;51:486-93.

157. Christenson RH, deFilippi CP, Kreutzer D. Biomarkers of ischemia in patients with known coronary artery disease: do interleukin-6 and tissue factor measurements during dobutamine stress echocardiography give additional insight? Circulation. 2005;112:3215-7.

159. Roe MT, Peterson ED, Li Y, Pollack CV Jr, Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, Gibler WB, Ohman EM. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2005;165:1870-6.

160. Turer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, Ohman EM. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005;6:12.

160. deFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46:35-44.

161. Apple FS, Parvin CA, Buechler KF, Christenson RH, Wu AH, Jaffe AS. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005;51:2198-200.

162. Azzazy, H.M., Pelsers, M.M., Christenson, R.H. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem., Jan; 52(1):19-29, 2006.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 18

163. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS., B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures., Am Heart J. 2006 Dec;152(6):1071-6.

164. Christenson RH, Tang WH., Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements., Med Gen Med. 2006 May 31;8(2):62.

165. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV., Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department., Am Heart J. 2006 Aug;152(2):253-62.

166. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Panteghini M, Welch MJ, Wu AH, Kahn SE., Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem. 2006 Sep;52(9):1685-92.

167. Shah KB, Nolan MM, Rao K, Wang DJ, Christenson RH, Shanholtz CB, Mehra MR, Gottlieb SS., The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients., Am J Med. 2007 Dec;120(12):1071-7.

168. Christenson RH, Apple FS, Cannon CP, Francis GS, Jesse RL, Morrow DA, Newby LK, Ravkilde J, Storrow AB, Tang WH, Wu AH., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure., Clin Biochem. 2008 Mar;41(4-5):210-21.

169. Christenson RH, Apple FS, Cannon CP, Frances GS, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Wu AH, Jaffe AS, Pagani F, Tate J, Ordonez-Llanos J, Mair J., National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure., Clin Biochem. 2008 Mar;41 (4-5):222-6.

170. Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, Newby LK, Ravkilde J, Tang WH, Christenson RH; NACB Committee, Cannon CP, Storrow AB., National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007 Dec;53(12):2086-96.

171. Shah MR, Hasselblad V, Tasissa G, Christenson RH, Binanay C, O'Connor CM, Ohman EM, Stevenson LW, Califf RM., Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol. 2007 Nov 1;100(9):1427-33.

172. deFilippi CR, Thorn EM, Aggarwal M, Joy A, Christenson RH, Duh SH, Jeudy J, Beache G., Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance., Am J Cardiol. 2007 Sep 1;100(5):885-9.

173. Azzazy HM, Christenson RH, Duh SH., Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems., Clin Chim Acta. 2007 Sep;384(1-2):176-8.

174. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J; National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine., National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure., Circulation. 2007 Jul 31;116(5):e95-8.

175. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH. National Academy of Clinical Biochemistry Laboratory Medicine., National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure., Circulation. 2007 Jul 31;116(5):e99-109.

176. deFilippi CR, Seliger SL, Maynard S, Christenson RH., Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem. 2007 Aug;53(8):1511-9.

177. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH; National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage., National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes., Circulation. 2007 Apr 3;115(13):e352-5.

178. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH; National Academy of Clinical Biochemistry., National Academy of Clinical Biochemistry Laboratory Medicine Practice

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 19

Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes., Circulation. 2007 Apr 3;115(13):e356-75.

179. Christenson RH; National Academy of Clinical Biochemistry., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure., Clin Chem. 2007 Apr;53(4):545-6

180. Christenson RH. Evidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing., Ann Clin Biochem. 2007 Mar;44(Pt 2):111-30.

181. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL., Relationship of depression to death or hospitalization in patients with heart failure., Arch Intern Med. 2007 Feb 26;167(4):367-73.

182. Nichols JH, Christenson RH, Clarke W, Gronowski A, Hammett-Stabler CA, Jacobs E, Kazmierczak S, Lewandrowski K, Price C, Sacks DB, Sautter RL, Shipp G, Sokoll L, Watson ID, Winter W, Zucker ML; National Academy of Clinical Biochemistry., Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing, Clin Chim Acta. 2007 Apr;379(1-2):14-28 discussion 29-30.

183. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW., National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009 Feb;55(2):378-84.

184. Hinderliter AL, Blumenthal JA, O'Conner C, Adams KF, Dupree CS, Waugh RA, Bensimhon D, Christenson RH, Sherwood A. Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure., Am Heart J. 2008 Dec;156(6):1191-5.

185. Shah KB, Kop WJ, Christenson RH, Diercks DB, Kuo D, Henderson S, Hanson K, Mehra MR, deFilippi CR., Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem 2009 Jan;55(1):59-67.

186. Christenson RH, Azzazy HM., Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms. Clin Biochem. 2009 Feb;42(3):150-7.

187. Christenson RH., What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care? Clin Chem Lab Med. 2008;46(11):1524-32.

188. Panteghini M, Bunk DM, Christenson RH, Katrukha A, Porter RA, Schimmel H, Wang L, Tate JR; IFCC Working Group on Standardization of Troponin I., Standardization of troponin I measurements: an update. Clin Chem Lab Med. 2008;46(11):1501-6.

189. Price CP , Christenson RH. Evaluating new diagnostic technologies: perspectives in the UK and US., Clin Chem. 2008 Sep;54(9):1421-3.

190. Luckenbill KN , Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate J, Wu AH, Ler R, Apple FS., Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage., Clin Chem. 2008 Mar;54(3):619-21.

191. Ordonez-Llanos J , Collinson PO, Christenson RH., Amino-terminal pro-B-type natriuretic peptide: analytic considerations., Am J Cardiol. 2008 Feb 4;101(3A):9-15.

192. Azzazy H, Mansour MM, Christenson RH. Gene Doping: Of Mice and Men., Clin Biochem. 2009Apr;42(6):435-41.193. Christenson RH, Azzazy HM, Duh SH, Maynard S, Seliger SL, Defilippi CR. Impact of increased body mass index

on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin Chem. 2010;56(4):633-41.

194. deFilippi CR , de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.

195. Noble JE , Bunk DM, Christenson RH, Cole KD, He HJ, Katrukha AG, Panteghini M, Porter RA, Schimmel H, Tate JR, Wang L. Development of a candidate secondary reference procedure (immunoassay based measurement procedure of higher metrological order) for cardiac troponin I: I. Antibody characterization and preliminary validation. Clin Chem Lab Med. 2010 Nov;48 (11):1603-10.

196. Shah KB , Kop WJ, Christenson RH, Diercks DB, Kuo D, Henderson S, Hanson K, deFilippi CR. Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. Clin Biochem. 2010;43:1405-10.

197. Socrates T , deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med. 2010;268:493-500.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 20

198. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol. 2010;56:343-51.

199. Tate JR, Bunk DM, Christenson RH, Katrukha A, Noble JE, Porter RA, Schimmel H, Wang L, Panteghini M. Standardisation of cardiac troponin I measurement: past and present. Pathology. 2010;42(5):402-8.

200. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152(10):640-8.

201. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-76.

202. Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin. Chem. 2010;56(1):21-33.

203. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J. Am. Coll. Cardiol. 2010;55(5):441-450.

204. Cullen L, Than M, Brown AFT, Christenson RH, Jaffe A. Comprehensive standardized data definitions for acute coronary syndrome research in emergency departments in Australasia. Emerg Med Australas. 2010;22(1):35-55.

205. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43(7-8):683-90.

206. van den Broek KC, Defilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol. 2011; Mar 1;107(5):723-9.

207. Christenson RH, Phillips D. Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name. Pathology. 2011 Apr;43(3):213-9.

208. Sherwood A, Blumenthal JA, Hinderliter AL, Koch GG, Adams KF Jr, Dupree CS, Bensimhon DR, Johnson KS, Trivedi R, Bowers M, Christenson RH, O'Connor CM. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol. 2011 Jan 25;57(4):418-23.

209. Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, Li SY, Defilippi CR. Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection Fraction. Clin Chem. 2011; Jun; 57(6):874-82.

210. Christenson RH, Snyder SR, Shaw CS, Derzon JH, Black RS, Mass D, Epner P, Favoretto AM, Liebow EB. Laboratory Medicine Best Practices: Systematic Evidence Review and Evaluation Methods for Quality Improvement. Clin Chem. 2011Jun;57(6):816-25.

211. Morjana N, Yau H, Rea D, Ruttle D, Jones H, Siefring G Jr, Christenson R. The Emit® 2000 Cyclosporine Specific Assay, Extended Range: development of an application protocol for the V-Twin® analyzer. Biotechnol Appl Biochem. 2011 Nov-Dec;58(6):476-82.

212. Liebow EB, Derzon JH, Fontanesi J, Favoretto AM, Baetz RA, Shaw C, Thompson P, Mass D, Christenson R, Epner P, Snyder SR. Effectiveness of automated notification and customer service call centers for timely and accurate reporting of critical values: a laboratory medicine best practices systematic review and meta-analysis. Clin Biochem. 2012 Sep;45(13-14):979-87.

213. Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Anand IS, Wu AH, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Filippatos GS, Di Somma S, Ng L, Neath SX, Christenson R, Morgenthaler NG, Anker SD, Maisel AS. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail. 2012 Jan;14(1):22-31.

214. Kavsak PA, Hammett-Stabler C, Lai L, Wallemacq P, Christenson RH. The ABCs of clinical biochemistry. Clin Biochem. 2012 Jan;45(1-2):1-2.

215. Collinson PO, Heung YM, Gaze D, Boa F, Senior R, Christenson R, Apple FS. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem. 2012 Jan;58(1):219-25.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 21

216. Edelman MJ, Hodgson L, Wang X, Christenson R, Jewell S, Vokes E, Kratzke R. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011 Nov;6(11):1902-6.

217. Christenson RH, Bunk DM, Schimmel H, Tate JR; IFCC Working Group on Standardization of Troponin I. Point: Put simply, standardization of cardiac troponin I is complicated. Clin Chem. 2012 Jan;58(1):165-8.

218. deFilippi CR, Christenson RH, Kop WJ, Gottdiener JS, Zhan M, Seliger SL. Left ventricular ejection fraction assessment in older adults: an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death? J Am Coll Cardiol. 2011 Sep 27;58(14):1497-506.

219. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS.

Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011 Sep;18(9):947-58. 221. deFilippi CR, de Lemos JA, Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS, Gottdiener JS, Seliger SL.J. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure

risk in older adults. Am Coll Cardiol. 2012 Dec 18;60(24):2539-47. 222. Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA, Fesmire FM, Geraci SA, Gersh BJ,

Larsen GC, Kaul S, McKay CR, Philippides GJ, Weintraub WS. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.J Am Coll Cardiol. 2012 Dec;60(23):2427-63.

223. Christenson RH, Huebner T. Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 Study. Clin Biochem. 2012 Nov;45(16-17):1276-7.

224. Christenson RH. Preamble: 'Evidence in Action: the Laboratory Medicine Best Practice initiative. Clin Biochem. 2012 Sep;45(13-14):977-8.

225. Aaron KJ, Kempf MC, Christenson RH, Wilson CM, Muntner P, Shrestha S.J Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.Acquir Immune Defic Syndr. 2012 Dec 1;61(4):499-506.

226. Christenson RH, Duh SH. Methodological and analytic considerations for blood biomarkers. Prog Cardiovasc Dis. 2012 Jul-Aug;55(1):25-33..

227. deFilippi C, Seliger SL, Kelley W, Duh SH, Hise M, Christenson RH, Wolf M, Gaggin H, Januzzi J. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 2012 Sep;58(9):1342-51

228. Snyder SR, Favoretto AM, Derzon JH, Christenson RH, Kahn SE, Shaw CS, Baetz RA, Mass D, Fantz CR, Raab SS, Tanasijevic MJ, Liebow EB. Effectiveness of barcoding for reducing patient specimen and laboratory testing identification errors: a Laboratory Medicine Best Practices systematic review and meta-analysis..Clin Biochem. 2012 Sep;45(13-14):988-98.

229. Snyder SR, Favoretto AM, Baetz RA, Derzon JH, Madison BM, Mass D, Shaw CS, Layfield CD, Christenson RH, Liebow EB. Effectiveness of practices to reduce blood culture contamination: a Laboratory Medicine Best Practices systematic review and meta-analysis..Clin Biochem. 2012 Sep;45(13-14):999-1011.

230. Kop WJ, Gottdiener JS, deFilippi CR, Barasch E, Seliger SL, Jenny NS, Christenson RH Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged >=65 years with heart failure. Circ Heart Fail. 2012 Jul 1;5(4):406-13. .

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 22

231. Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. Thorac Oncol. 2012 Apr;7(4):649-54.

232. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Christenson RH, Potocki M, McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenthaler NG, Anker SD. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail. 2012 Mar;14(3):278-86.

233. Kavsak PA, Hammett-Stabler C, Lai L, Wallemacq P, Christenson RH. The ABCs of clinical biochemistry. Clin Biochem. 2012 Jan;45(1-2):1-2.

234. Christenson RH, Bunk DM, Schimmel H, Tate JR; IFCC Working Group on Standardization of Troponin I. Point: Put simply, standardization of cardiac troponin I is complicated. .Clin Chem. 2012 Jan;58(1):165-8.

235. Christenson RH, Cervelli DR, Sterner J, Bachmann LM, Rebuck H, Gray J, Kelley WE. Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System. Clin Biochem. 2011 Sep;44(13):1128-36.

236. van den Broek KC, Defilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol. 2011 Mar 1;107(5):723-9.

238. Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol EJ, Califf RM, Van de Werf F, Armstrong PW; PARAGON-B Investigators. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 5;41(3):371-80.

239. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001 Jun 19;103(24):2891-6.

240 Christenson RH, Vollmer RT, Ohman EM, Peck S, Thompson TD, Duh SH, Ellis SG, Newby LK, Topol EJ, Califf RM. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. Am J Cardiol. 2000 Mar 1;85(5):543-7.

241. Broyles DL, Nielsen RG, Bussett EM, Lu WD, Mizrahi IA, Nunnelly PA, Ngo TA, Noell J, Christenson RH, Kress BC. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem. 1998 Oct;44(10):2139-47.

241. Christenson RH, Ohman EM, Topol EJ, O'Hanesian MA, Sigmon KN, Duh SH, Kereiakes D, Worley SJ, George BS, Pizzo CK. Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group. Clin Chem. 1995 Jun;41(6 Pt 1):844-52

242. Ohman EM, Christenson RH, Califf RM, George BS, Samaha JK, Kereiakes DJ, Worley SJ, Wall TC, Berrios E, Sigmon KN, Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. Am Heart J. 1993 Oct;126(4):819-26.

243. Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013 Mar;44(3):714-9.

244. Miller WG, Myers GL, Gantzer ML, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Stanley GL, Nubling CM, Sturgeon CM. Klin Lab Diagn. 2013 Feb;(2):54-61. [Article in Russian]

245. Price CP, Christenson RH. Ask the right question: a critical step for practicing evidence-based laboratory medicine.Ann Clin Biochem. 2013;50:306-14.

246. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2013 Jun 6. doi: 10.1002/hep.26556. [Epub ahead of print]

247. Hicks CW, Engineer RS, Benoit JL, Dasarathy S, Christenson RH, Peacock WF. Procalcitonin as a biomarker for early sepsis in the emergency department. Eur J Emerg Med. 2013 May 10. [Epub ahead of print]

248. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, Nowak RM, Vilke G, Daniels LB, Hollander JE, Apple FS, Cannon C, Nagurney JT, Schreiber D, Defilippi C, Hogan C, Diercks

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 23

DB, Stein JC, Headden G, Limkakeng AT Jr, Anand I, Wu AH, Papassotiriou J, Hartmann O, Ebmeyer S, Clopton P, Jaffe AS, Peacock WF. Copeptin Helps in the Early Detection of Patients With Acute Myocardial Infarction: Primary Results of the CHOPIN Trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol. 2013;62:150-60.

249 Wu AH, Christenson RH. Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. Clin Biochem 2013;46:969-78.

250. Beatty AL, Ku IA, Christenson RH, DeFilippi CR, Schiller NB, Whooley MA. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med 2013;173):763-9.

251. Mishra RK, Li Y, Ricardo AC, Yang W, Keane M, Cuevas M, Christenson R, deFilippi C, Chen J, He J, Kallem RR, Raj DS, Schelling JR, Wright J, Go AS, Shlipak MG Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). Am J Cardiol. 2013 Feb 1;111(3):432-8.

252. Barth JH, Panteghini M, Bunk DM, Christenson RH, Katrukha A, Noble JE, Schimmel H, Wang L, Tate JR; for the IFCC Working Group on Standardization of Cardiac Troponin I. Recommendation to harmonize the units for reporting cardiac troponin results. Clin Chim Acta. 2013 Nov 8. pii: S0009-8981(13)00436-1. doi: 10.1016/j.cca.2013.10.023.

253. Owen WE, Lambert-Messerlian G, Delaney C, Christenson R, Plouffe B, Ludewig R, Woods A, Lei JD , Thompson S, Roberts WL, Straseski JA. Multisite evaluation of a monoclonal IMMULITE erythropoietin immunoassay.Clin Biochem. 2014 Feb;47(3):216-9

254. Migrino RQ, Harmann L, Christenson R, Hari P.Heart Vessels. Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. 2013 Oct 19. [Epub ahead of print]

255. Christenson E, Christenson RH. The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Ann Lab Med. 2013 Sep;33(5):309-18.

256. Christenson E, Christenson RH. The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Ann Lab Med. 2013 Sep;33(5):309-18..257. Smith K, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M,

Christenson R, Wolf M, Januzzi J. Fibroblast growth factor 23, high-sensitivity cardiac troponin,and left ventricular hypertrophy in CKD. Am J Kidney Dis. 2013 Jan;61(1):67-73.258 Gaggin HK, Dang PV, Do LD, Defilippi CR, Christenson RH, Lewandrowski EL, Lewandrowski KB, Truong

BQ, Pham VQ, Vu VH, Vu TV, Nguyen TB, Belcher AM, Femia A, Kelley C, Januzzi JL. Reference Interval Evaluation of High Sensitivity Troponin T and N-Terminal B-Type Natriuretic Peptide in Vietnam and the US: The North South East West Trial. Clin Chem. 2014 May;60(5):758-64.

259 Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014 Apr 15;63(14):1441-8.

260 Liquori ME, Christenson RH, Collinson PO, Defilippi CR. Cardiac biomarkers in heart failure.Clin Biochem. 2014 Apr;47(6):327-337.

261 Christenson ES, Collinson PO, Defilippi CR, Christenson RH. Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Rev Mol Diagn. 2014 Mar;14(2):185-97.

262 Roberts NW, Christenson RH, Price CP. Searching for evidence: a guide to finding the evidence in laboratory medicine. Ann Clin Biochem. 2014 May;51(Pt 3):326-34.

263 Hicks CW, Engineer RS, Benoit JL, Dasarathy S, Christenson RH, Peacock WF. Procalcitonin as a biomarker for early sepsis in the emergency department.Eur J Emerg Med. 2014 Apr;21(2):112-7.

264 Collinson PO, Garrison L, Christenson RH.Clin Biochem. Cardiac biomarkers - A short biography 2014 Nov 22. pii: S0009-9120(14)00773-5. doi: 10.1016/j.clinbiochem.2014.11.014. [Epub ahead of print]

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 24

265. Bansal N, Hyre Anderson A, Yang W, Christenson RH, deFilippi CR, Deo R, Dries DL, Go AS, He J, Kusek JW, Lash JP, Raj D, Rosas S, Wolf M, Zhang X, Shlipak MG, Feldman HI. High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2015 Apr;26(4):946-56. 

266. Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, Lopes RD, Green CL, Lincoff AM, Armstrong PW, Roe MT. Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J. 2014 Oct;168(4):503-511.

267. Storrow AB, Nowak RM, Diercks DB, Singer AJ, Wu AH, Kulstad E, LoVecchio F, Fromm C, Headden G, Potis T, Hogan CJ, Schrock JW, Zelinski DP, Greenberg MR, Christenson RH, Ritchie JC, Chamberlin JS, Bray KR, Rhodes DW, Trainor D, Southwick PC. Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. Clin Biochem. 2015 Mar;48(4-5):260-7.

268. Storrow AB, Christenson RH, Nowak RM, Diercks DB, Singer AJ, Wu AH, Kulstad E, LoVecchio F, Fromm C, Headden G, Potis T, Hogan CJ, Schrock JW, Zelinski DP, Greenberg MR, Ritchie JC, Chamberlin JS, Bray KR, Rhodes DW, Trainor D, Holmes D, Southwick PC. Diagnostic performance of cardiac Troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. Clin Biochem. 2015 Mar;48(4-5):254-9.

269. Christenson RH, Kassed CA. Harmonized laboratory results are in tune with effective healthcare goals. J Comp Eff Res. 2014 May;3(3):221-4.

270. Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR, Seliger SL, Weir MR. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014;39(6):543-52.

271. Shafi T, Zager PG, Sozio SM, Grams ME, Jaar BG, Christenson RH, Boulware LE, Parekh RS, Powe NR, Coresh J. Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis. 2014 Sep;64(3):443-51.

272. Beatty AL, Ku IA, Bibbins-Domingo K, Christenson RH, DeFilippi CR, Ganz P, Ix JH, Lloyd-Jones D, Omland T, Sabatine MS, Schiller NB, Shlipak MG, Skali H, Takeuchi M, Vittinghoff E, Whooley MA.Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. J Am Heart Assoc. 2015 Jul 6;4(7).

273. Mindikoglu AL, Dowling TC, Schaub DJ, Hutson WR, Potosky DR, Christenson RH, Barth RN, LaMattina JC, Hanish SI, Weir MR, Raufman JP. Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Jul 5. [Epub ahead of print]

274. Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR, Howell C. Estimation of Glomerular Filtration Rate in Patients with Cirrhosis using New and Conventional Filtration Markers and Dimethylarginines. Clin Gastroenterol Hepatol. 2015 Jun 29. pii: S1542-3565(15)00845-9.

275. Marston NA, Shah KS, Mueller C, Neath SX, Christenson RH, McCord J, Nowak RM, Daniels LB, Hollander JE, Apple F, Nagurney J, Schreiber D, deFilippi C, Diercks D, Limkakeng A, Anand IS, Wu AH, Jaffe AS, Peacock WF, Maisel AS. Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. Emerg Med J. 2015 Jun 23. pii: emermed-2015-204692. doi: 10.1136/emermed-2015-204692. [Epub ahead of print]

276. Tate JR, Bunk DM, Christenson RH, Barth JH, Katrukha A, Noble JE, Schimmel H, Wang L, Panteghini M. Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clin Chem Lab Med. 2015 Apr;53(5):677-90.

277. Shah KS, Marston NA, Mueller C, Neath SX, Christenson RH, McCord J, Nowak RM, Vilke GM, Daniels LB, Hollander JE, Apple FS, Cannon CM, Nagurney J, Schreiber D, deFilippi C, Hogan CJ, Diercks DB, Limkakeng A, Anand IS, Wu AH, Clopton P, Jaffe AS, Peacock WF, Maisel AS. Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. Acad Emerg Med. 2015 May;22(5):554-63.

278. Layfield C, Rose J, Alford A, Snyder SR, Apple FS, Chowdhury FM, Kontos MC, Newby LK, Storrow AB, Tanasijevic M, Leibach E, Liebow EB, Christenson RH. Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. Clin Biochem. 2015 Mar;48(4-5):204-12.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 25

279. Gottlieb SS, Harris K, Todd J, Estis J, Christenson RH, Torres V, Whittaker K, Rebuck H, Wawrzyniak A, Krantz DS. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem. 2015 Mar;48(4-5):292-6.

280. Collinson PO, Garrison L, Christenson RH. Cardiac biomarkers - A short biography. Clin Biochem. 2015 Mar;48(4-5):197-200.

281. Wu AH, Christenson RH. The standards for reporting diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate? Ann Transl Med. 2016 Feb;4(3):44.

282. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B; Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T.TRAPID-AMI Investigators..Ann Emerg Med. 2016 Jan 8. pii: S0196-0644(15)01501-2.

283. Price CP, Christenson RH. Critical appraisal in the practice of laboratory medicine.Ann Clin Biochem. 2016 Mar;53(Pt 2):222-32.

284. Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR, Howell CD. Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines.Clin Gastroenterol Hepatol. 2016 Apr;14(4):624-632

285. Marston NA, Shah KS, Mueller C, Neath SX, Christenson RH, McCord J, Nowak RM, Daniels LB, Hollander JE, Apple F, Nagurney J, Schreiber D, deFilippi C, Diercks D, Limkakeng A, Anand IS, Wu AH, Jaffe AS, Peacock WF, Maisel AS.Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. Emerg Med J. 2016 Jan;33(1):23-9.

286. Bansal N, Katz R, Seliger S, DeFilippi C, Sarnak MJ, Delaney JA,Christenson R, de Boer IH, Kestenbaum B, Robinson-Cohen C, Ix JH, Shlipak MG.Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS). Am J Kidney Dis. 2016 Jun;67:994-6.

287. Giannitsis E, Biener M, Vafaie M, deFilippi CR, Christ M, Santalo-Bel M, Panteghini M, Plebani M, Verschuren F, Jernberg T, French JK, Christenson RH, Body R, McCord J, Dilba P, Katus HA, Mueller C Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - Sub-analysis from the TRAPID-AMI study. Mueller-Hennessen M, Lindahl B,; TRAPID-AMI Investigators. Int J Cardiol. 2016 Apr 15;209:26-33.

288. McEvoy JW, Chen Y, Halushka MK, Christenson E, Ballantyne CM, Blumenthal RS, Christenson RH, Selvin E.Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites. J Am Heart Assoc. 2016 May 13;5(5).

289. Body R, Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, de Filippi CR, Nowak R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French JK, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B The Use of Very Low Concentrations of High-sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. Acad Emerg Med. 2016 Sep;23(9):1004-13.

290. Fitch KV, DeFilippi C, Christenson R, Srinivasa S, Lee H, Lo J, Lu MT, Wong K, Petrow E, Sanchez L, Looby SE, Hoffmann U, Zanni M, Grinspoon SK Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 Sep 10;30(14):2205-14.

291. Collinson P, Hammerer-Lercher A, Suvisaari J, Apple FS, Christenson RH, Pulkki K, van Dieijen-Visser MP, Duff CJ, Baum H, Stavljenic-Rukavina A, Aakre KM, Langlois MR, Stankovic S, Laitinen P; How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE). Working Group for Cardiac Markers, European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2016 Sep;62(9):1264-71.

292. Parikh RH, Seliger SL, Christenson R, Gottdiener JS, Psaty BM, deFilippi CR.Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling Population. J Am Heart Assoc. 2016 Aug 1;5(8). 

293. deFilippi CR, de Lemos JA, Newman AB, Guralnik JM, Christenson RH, Pahor M, Church T, Espeland M, Krithevsky SB, Stafford R, Seliger SL. Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention. LIFE Study Group. Am Heart J. 2016 Sep;179:151-6.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 26

295. Price CP, John AS, Christenson R, Scharnhorst V, Oellerich M, Jones P, Morris HA. Leveraging the real value of laboratory medicine with the value proposition. Clin Chim Acta. 2016 Sep 17;462:183-186.

296. Palme S, Christenson RH, Jortani SA, Ostlund RE, Kolm R, Kopal G, Laubender RP.Multicenter evaluation of analytical characteristics of the Elecsys® Periostin immunoassay. Clin Biochem. 2016 Oct 8.

297. Paramjit K. Sandhu, Salma M.A. Musaad, Alan T. Remaley, Stephanie S. Buehler, Sonya Strider, James H. Derzon, Hubert W. Vesper,Anne Ranne, Colleen S. Shaw, Robert H. Christenson. Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. JALM Sep 2016, 1 (2) 214-229.

298. Mueller-Hennessen M, Mueller C, Giannitsis E, Biener M, Vafaie M, deFilippi CR, Christ M, Ordóñez-Llanos J, Panteghini M, Plebani M, Verschuren F, Melki D, French JK, Christenson RH, Body R, McCord J, Dinkel C, Katus HA, Lindahl B1.Serial sampling of high-sensitivity cardiac troponin T may not be required for prediction of acute myocardial infarction diagnosis in chest pain patients with highly abnormal concentrations at presentation. Clin Chem. 2016 Dec 8. pii: clinchem.2016.258392. [Epub ahead of print]

299. Juraschek SP, Miller ER 3rd, Selvin E, Carey VJ, Appel LJ, Christenson RH, Sacks FM. Effect of type and amount of dietary carbohydrate on biomarkers of glucose homeostasis and C reactive protein in overweight or obese adults: results from the OmniCarb trial. BMJ Open Diabetes Res Care. 2016 ;4(1):V:e000276.

300. DeFina LF, Willis BL, Radford NB, Christenson RH, deFilippi CR, de Lemos JA. Cardiorespiratory Fitness and Highly Sensitive Cardiac Troponin Levels in a Preventive Medicine Cohort. J Am Heart Assoc. 2016 Nov 28;5(12). pii: e003781.

301. Beri N, Marston NA, Daniels LB, Nowak RM, Schreiber D, Mueller C, Jaffe A, Diercks DB, Wettersten N, DeFilippi C, Peacock WF, Limkakeng AT, Anand I, McCord J, Hollander JE, Wu AH, Apple FS, Nagurney JT, Berardi C, Cannon CM, Clopton P, Neath SX, Christenson RH, Hogan C, Vilke G, Maisel A. Necessity of hospitalization and stress testing in low risk chest pain patients. Am J Emerg Med. 2016 Oct 29. pii: S0735-6757(16)30788-4. doi: 10.1016/j.ajem.2016.10.072. [Epub ahead of print]

302. Christenson RH, Jacobs E, Uettwiller-Geiger D, Estey MP, Lewandrowski K, Koshy TI, Kupfer K, Li Y, Wesenberg JC. Comparison of thirteen commercially available cardiac troponin assays in a multicenter north american study. JALM 2017;1;544-561.

303. Limkakeng AT, Drake W,Lokhnygina Y, HP, Shogilev D, Christenson R, Kristin Newby LK. Myocardial ischemia on exercise stress echocardiography Testing is not associated with changes in troponin t concentrations. JALM 2017;1;532-543.

304. Hammerer-Lercher A, Collinson PO, Suvisaari J, Christenson RH, Pulkki K, van Dieijen-Visser MP, Duff CJ, Baum H, Stavljenic-Rukavina A, Aakre KM, Langlois MR, Stankovic S, Laitinen P Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study JALM 2017;1:483-493.

Abstracts

1. Christenson, R.H. and McGlothlin, C.D. Differential assay of metanephrine and normetanephrine. Clin Chem 1978;24:1042.

2. Christenson, R.H. and McGlothlin, C.D. Quantitative determination of the metanephrines and catecholamines in urine via gas-liquid chromatography. Clin Chem 1980; 26:963.

3. Bustrack, J.A., Katz, M.D., Hull, J.H., Foster, J.R., Christenson, R.H., and Hammond, J.E. Effect of fluid volume on bioavailability of digoxin tablets and capsules. Drug Intell Clin Pharmacol 1981; 15:477.

4. Christenson, R.H., Hammond, J.E., Johnson, B.F., Hull, J.H., and Bustrack, J.A. Measurement of digoxin in urine. Clin Chem 1981; 27:1088.

5. Christenson, R.H., Silverman, L.M., Lengowski, K., Shaw, M., and Windfield, J.B. Interpretation of CSF/serum protein analysis in demyelinating diseases. Clin Chem 1982; 28:1568.

6. Christenson, R.H. and Silverman, L.M. The determination of urinary protein adapted to the beckman automated ICS. Clin Chem 1982; 28:1620.

7. Christenson, R.H. and Johnston, F.R. Adaptation and evaluation of a method for determination of 5’nucleotidase activity in serum. Clin Chem 1983; 29:1266.

8. Christenson, R.H., Johnston, F.R., Zwadyk, P.W., and Crews, B. Evaluation of the ames/gilford optimate system for therapeutic drug monitoring. Clin Chem 1983; 29:1238.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 27

9. Christenson, R.H., Silverman, L.M., Howard, J.F., and Belhmar, P. Protein in patients with various neurologic diseases. Clin Chem 1983; 29:1162.

10. Christenson, R.H., Tucker, J.A., and Allen, E.A. Evaluation of dipstick screening for elimination of urine culture and microscopic urinalysis. Clin Chem 1984; 30:980.

11. Winfield, J.B., Shaw, M., Lengowski, K., Christenson, R.H., and Silverman, L.M. Evidence for intrathecal IgG synthesis and blood brain impairment in CNS lupus. Pan-American Congress of Rheumatology.

12. Christenson, R.H. and Russell, M.E. Evaluation of centricon-30 microconcentrators for preconcentration of cerebrospinal fluid (CSF) specimens prior to agarose electrophoresis. Clin Chem 1985; 31:972.

13. Christenson, R.H., Dent, G.A., and Tuszynski, A. Results of two vitamin B-12 and folic acid assays compared in a reference interval study. Clin Chem 1985; 31:1025.

14. Christenson, R.H., Scroggs, M.W., and Odom, J.D. A persistent lactate dehydrogenase flipped isoenzyme pattern (LDI > LD2) in a patient with small-cell carcinoma. Clin Chem 1986; 32:1129.

15. Christenson, R.H., Studenberg, S.D., Sedor, F.A., and Beck-Davis, S. Elimination of digoxin-like immunoreactivity prior to digoxin measurement by fluorescence polarization immunoassay. Clin Chem 1987; 33:914.

16. Sachs, C.W., Christenson, R.H., Pratt, P.C., and Lynn, W.S. Neutrophil elastase activity in differentiating HL-60 promyelocytes by culture with ethanol and elastase deficient neutrophils are produced in alcoholics. Federation Proceedings 1987; 46:2017.

17. Christenson, R.H., Russell, M.E., and Bell, Y.L. Immunoassays for immunoglobulin-G in cerebrospinal fluid compared. Clin Chem 1988; 34:1158.

18. Roeback, J.R., Christenson, R.H., Watson, T.E., and Hla, K.M. Total cholesterol measurements: reliability of testing on separate days with and without duplicate analysis. Clin Chem 1988; 34:1229.

19. Christenson, R.H., Albright, R.E., Habig, R.L., and Schneider, K.A. Establishment of CSF TRAP: a method to improve cerebrospinal fluid testing. Clin Chem 1988; 34:1244.

20. Greenberg, S.J., Marcon, L., Hurwitz, B.J., Christenson, R.H., Waldmann, T.A., and Nelson, D.L. Soluble interleukin-2 receptor in multiple sclerosis. J Cell Biochem 1988; 27:12E.

21. Christenson, R.H., Toffaletti, J., Ohman, E.M., Clemmensen, P., and Wagner, G.S. Four assays for creatine kinase-MB compared. Clin Chem 1989; 35:1124.

22. Christenson, R.H., Ohman, E.M., Clemmensen, P., and Wagner, G.S. Use of creatine kinase-MB isoforms for predicting myocardial reperfusion. Clin Chem 1989; 35:1125.

23. Christenson, R.H., Ohman, E.M., Clemmensen, P., and Wagner, G.S. Creatine kinase MM3/MMI and MB2/MBI isoform ratios after reperfusion in patients with myocardial infarction. Circulation 1989; 80:513.

24. Christenson, R.H., Russell, M.E., and Pizzo, C.M. Creatine kinase-MB isoforms fractionated by immunoprecipitation and quantified in a rapid analyzer. Clin Chem 1990; 36:1127.

25. Christenson, R.H., Ohman, E.M., Clemmensen, P., Grande, P., and Wagner, G.S. Assay dependency for assessing creatine kinase-MB release after reperfusion. Clin Chem 1990; 36:1129.

26. Christenson, R.H., Ohman, E.M., Clemmensen, P., and Wagner, G.S. Release of the tissue isoforms of creatine kinase, MM3 and MB2, is simultaneous after myocardial reperfusion. Clin Chem 1990; 36:824.

27. Ohman, E.M., Christenson, R.H., Sigmon, K.N., Flanagan, C.H., Frid, D.J., and Califf, R.M. Noninvasive detection of reperfusion after thrombolysis using rapid CK-MB analysis. Circulation 1990; 82:281.

28. Christenson, R.H., Ohman, E.M., Sigmon, K.N., and Flanagan, C.H. Release of the tissue specific MM-3 and MB-2 isoforms of creatine kinase is simultaneous during reperfusion after myocardial infarction. Circulation 1990;82:297.

29. Christenson, R.H., and Kreuter, J. Definitive separation of four possible isoforms of creatine kinase-MB. Electrophoresis 1991; 12:156.

30. Christenson, R.H., Kazanzides, D., and Pizzo, C.K. Verification of plasma based calibrators for use with the stratus creatine kinase (CK-MB) assay. Clin Chem 1991;37:912.

31. Christenson, R.H., Ohman, E.M., and Sigmon, K.N. Use of creatine kinase-MB and the MB isoforms for non-invasively assessing reperfusion after thrombolytic therapy in acute myocardial infarction (AMI) patients. Clin Chem 1991; 37:913.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 28

32. Christenson, R.H., Russell, M.E., and Pizzo, C.K. Specificity of an antibody for precipitating the MB1 isoform of creatine kinase-MB (CK-MB). Clin Chem 1991;37:1023.

33. Christenson, R.H. Non-invasive monitoring of thrombolysis after myocardial infarction. Clin Chem 1991; 37:1100.

34. Christenson, R.H., Chapman, R., and Martz, M.D. Free phenytoin measurement: empiric determination of the therapeutic range, cost of analysis, and turnaround delay. American Epilepsy Society. Epilepsia 1991; 32(3):55.

35. Christenson, R.H., Ohman, E.M., Wall, T.C., Sigmon, K.N., Martin, L.H., Chapekis, A.T., and Topol, E.J. Relationship between infarct related artery flow after thrombolytic therapy and release of tissue specific isoforms of creatine kinase. JACC 1992; 19:303A.

36. Christenson, R.H., Vaidya, H., Vuori, J., and Vaananen, K. Characteristics of myoglobin, carbonic anhydrase III, and the myoglobin/Carbonic Anhydrase III ratio after acute myocardial infarction. Clin Chem 1992; 38:983.

37. Miskinis, D.M., Lasky, F.D., Christenson, R.H., Person, N.B., and Stern, S.C. Determination of serum reference ranges for derived tests (globulin, % iron saturation, and osmolality) on the kodak ektachem analyzer. Clin Chem 1992; 38:1033.

38. Gregory, L.C., Duh, S.H., and Christenson, R.H. An evaluation of total cholesterol measurements by desk-top analyzers. Clin Chem 1992; 38:1037.

39. Duh, S.H., Gregory, L., and Christenson, R.H. Assay performance criteria for instruments used in cholesterol screening. Clin Chem 1992; 38: 1068.

40. Christenson, R.H., Martz, M.D., and Chapman, R. Therapeutic range for free phenytoin determined empirically. Clin Chem 1992; 38:995.

41. Gregory, L.C., Duh, S.H., Christenson, R.H., and Chenault, M.B. Analytical performance of desk-top analyzers in the measurement of total cholesterol. 1992 NCCLS Meeting, Philadelphia, PA.

42. Ohman, E.M., Christenson, R.H., Califf, R.M., Krucoff, M.W., Sigmon, K., Quintero, K., George, B.S., Ellis, S.G., and Topol, E.J. Clinical outcome based on a probability index for non-invasive detection of reperfusion. JACC 1993; 21:197A.

43. Christenson, R.H., Ohman, E.M., Duh, S.H., Sigmon, K.N., Klinker, K.A., Vollmer, R.T., and Wall, T.C. How well does time to peak enzyme concentration predict coronary patency after thrombolytic therapy? JACC 1993; 21:398A.

44. Christenson, R.H., Gregory, L.C., Duh, S.H., Mackenzie, C., and Trump, B.F. Hemoglobin based substitutes: Interference with routine chemical tests. Clin Chem 1993; 39:1129.

45. Panigrahi, K., Fisher, R., Reiss, O., and Christenson, R.H. Immunoradiometric assay for skeletal alkaline phosphatase: evaluation of analytical performance and determination of the normal reference interval. Clin Chem 1993; 39:1156.

46. Vaidya, H., Apple, F., Boches, F., Christenson, R., Jones, K., Landt, Y., Loyd, J., and Wu, A. Preparation of preliminary standards for creatine kinase-MB (CKMB) mass immunoassays. Clin Chem 1993; 39:1256-1257.

47. Christenson, R.H., Duh, S.H., and Zorn, N. Thyroid testing evaluated with three immunoassay systems. Clin Chem 1993; 39: 1208.

48. Christenson, R.H., Ohman, E.M., Sigmon, K.N., Berrios, E., Alonsozana, G.L., Smith, D.D., Duh, S., and Krucoff, M.W. Use of myoglobin for noninvasively assessing coronary reperfusion. Circulation 1993; 88:I-258.

49. Sprung, J., Mackenzie, C.F., Christenson, R.H., Hoff, B., Trump, B.F., and Winslow, R. High colloid oncotic pressure may increase mortality following hemoglobin solutions (hbs) for hemorrhagic shock resuscitation. Anesth 1993; 79:A570.

50. Sakamoto, R., Mackenzie, C.F., Russell, R., Christenson, R.H., and Trump, B.F. Use of hemoglobin solutions (Hbs) in renal ischemia caused by severe hemorrhagic shock. Anesth 1993; 79:A114.

51. Mackenzie, C.F., Parr, M., Christenson, R.H., Lankachandra, K., and Trump, B.F. The effect of free hemoglobin solutions (Hbs) on coagulation and hematology following resuscitation from severe hemorrhagic shock (HS) in dogs. Anesth 1993; 79:A269.

52. Williams, J., Mackenzie, C.F., Sprung, J., Hoff, H., Sakamoto, R., Lottes, M., Christenson, R.H., Russell, R., and Trump, B.F. Cardiorespiratory variables following resuscitation from severe hemorrhagic shock (HS) using hemoglobin solutions (Hbs). Anes 1993; 79:A569.

53. Christenson, R.H., Vollmer, R.T., Moos, S., Liprandi, M.I., Duh, S.H., Alonsozana, G.L., Absi, R.,

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 29

Canala, M., and Haiek, C. Curve-fitting release of myoglobin, total creatine kinase, creatine kinase-MB, and the MB2, and MB1 isoforms of CK after angioplasty. Clin Chem 1994; 40:1001-1002.

54. Gregory, L.C., Duh, S.H., Kurani, D., Alonsozana, G.L., Akingbe, O., and Christenson, R.H. An evaluation of lipid measurements by four compact analyzers. Clin Chem 1994; 40:1059.

55. Panigrahi, K., Gaines, S.M., Vigliotti, D., Duh, S.H., and Christenson, R.H. Immunoassays for whole blood cyclosporine A: evaluation and comparison between methods. Clin Chem 1994; 40:1084.

56. Alonsozana, G.L., Kurani, D., Duh, S.H., Cowfer, J., Rodriguez, S., and Christenson, R.H. Temporal characteristics of myoglobin among non-MI patients in a chest pain evaluation center. Clin Chem 1994; 40:1123.

57. Kurani, D.D., Duh, S.H., and Christenson, R.H. Cardiac troponin-T measurement in serum after storage in plastic vials at –70oC. Clin Chem 1994; 40:1125.

58. Panigrahi, K., Ryan, W., and Christenson, R.H. Comparative characteristics of total ALP, B-ALP by ostase, and B-ALP by electrophoretic method in Paget’s disease patients. Clin Chem 1994; 40:1125.

59. Christenson, R.H. Cardiovascular markers. Clin Chem 1994; 40:1171.60. Christenson, R.H. Biochemical markers of myocardial injury: an overview. Clin Chem 1994;

40:1171. 61. Ohman, E.M., Armstrong, P., Califf, R.M., O’Hanesian, M., Hamm, C.W., Katus, H., Granger,

C.B., Christenson, R.H., Cianciolo, C., and Topol, E.J. Risk stratification in acute coronary syndromes using serum troponin T. JACC 1995; 25:148A.

62. Christenson, R.H., Ohman, E.M., Sigmon, K.N., O’Hanesian, M., Alonsozana, G.L., Newby, K.L., Duh, S.H., Krucoff, M.W., and Califf, R.M. Combining myoglobin and clinical variables for assessing coronary reperfusion after thrombolytic therapy. JACC 1995;25:148A.

63. Elfath, M.D., Christenson, R.H., Alonsozana, G., and Kurani, D. Effects of hemoglobin solution used as a red cell substitute on typing or red cells and screening for antibodies in the serum. Am J Clin Path 1995; 103:520.

64. Christenson, R.H. Real-time requirements for biochemical markers of myocardial injury: What situations? What markers? What performing sites? Clin Chem 1995; 41:S274.

65. Alonsozana, G., Duh, S.H., and Christenson, R.H. Comparison of creatine kinase-MB, total creatine kinase, and cardiac troponin I in healthy individuals and suspected myocardial infarction patients. Clin Chem 1995; 41:S150-S151.

66. Alonsozana, G., Duh, S.H., Ohman, E.M., Cianciolo, C., O’Hanesian, M.A., and Christenson, R.H. Estimation of the analytical cutoff in EDTA plasma for a rapid assay device for cardiac troponin T. Clin Chem 1995; 41:S154.

67. Duh, S.H., Alonsozana, G., and Christenson, R.H. Evaluation of an up and down method for estimating the sensitivity of qualitative tests. Clin Chem 1995; 41:S198.

68. Christenson, R.H., O’Hanesian, M.A., Newby, L.K., Duh, S.H., O’Connor, C., Worley, S., George, B., Vollmer, R.T., Sigmon, K.A., and Ohman, E.M. Relation of area under the CK-MB curve and ventriculographic and clinical outcomes in myocardial infarction patients treated with thrombolytic therapy. Eu Heart J 1995; 16:122 Supplement.

69. Ohman, E.M., Armstrong, P.A., Califf, R.M., O’Hanesian, M.A., Hamm, C.W., Katus, H., Granger, C.B., Christenson, R.H., Cianciolo, C., and Topol, E.J. Risk stratification in acute ischaemic syndromes using serum troponin T. Eu Heart J 1995; 16:122 Supplement.

70. Christenson, R.H., Armstrong, P.A., O’Hanesian, M.A., Hamm, C.W., Katus, H., Cianciolo, C., and Ohman, E.M. The value of troponin T measurements for risk stratification in patients with acute ischemic syndromes. Circulation 1995; 93; I-663 Supplement.

71. Christenson, R.H., Alonsozana, G.L., Duh, S.H., and Ochs, L. Cutoff for a rapid whole blood cardiac troponin T assay. JACC 1996; 27:358A Supplement.

72. Elfath, M.D., Christenson, R.H., Alonsozana, G.L., Mackenzie, C.F., and Trump, B.F. Changes in the prothrombin time (PT), activated partial thromboplastin time (PTT) and fibrinogen level in response to a hemoglobin solution used as a red cell substitute. Am J Clin Path 1996; 105:507.

73. Elfath, M.D., Christenson, R.H., Alonsozana, G.L., Mackenzie, C.F., and Trump, B.F. Effects of a hemoglobin solution used as a red cell substitute on platelet aggregation. Am J Clin Path 1996; 105:507.

74. Kurani, D. and Christenson, R.H. Evaluation of the axsym ultrasensitive hTSH assay. Clin Chem

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 30

1996; 42:S157.75. Kurani, D. and Christenson, R.H. Comparison of CA125 assays on the axsym and the Imx systems.

Clin Chem 1996; 42:S157.76. Duh, S.H., Alonsozana, G.L., and Christenson, R.H. Modified up-and-down method for estimating

extreme sensitivity of qualitative tests. Clin Chem 1996; 42:S136.77. Alonsozana, G.L., Jacobs, E., Fitzgerald, R.L., Frankel, W.L., Ochs, L., and Christenson, R.H.

Cardiac troponin T: Comparison of a whole blood rapid assay with the ES 300 assay in cardiac patients. Clin Chem 1996; 42:S179.

78. Azzazy, H.M. and Christenson, R.H. Digoxin testing with stratus II, axsym pre-treatment digoxin, and axsym non pre-treatment digoxin. Clin Chem 1996; 42:S205.

79. Ohman, E.M., Christenson, R.H., Peck, S., Pieper, K., Katus, H., Newby, K., and Armstrong, P. Comparison of troponin I and T for risk stratification in patients with acute coronary syndromes. Circulation 1996; 94:I-323.

80. Chou, P.P., Tsushima, J.H., Troxil, S., Azzazy, H.M.E., Christenson, R.H., Chiappetta, E., and Avers, R.J. A multi-site evaluation of the abbott axsym vancomycin II. Clin Chem 1997; 43:S208.

81. Ambrozak, D.R., Azzazy, H.M.E., Cummings, P., and Christenson, R.H. Generation and characterization of murine monoclonal antibodies to human carbonic anhydrase III. Clin Chem 1997; 43:S244.

82. Abubaker, J.A.M., Azzazy, H.M.E., Cummings, P., and Christenson, R.H. Using multiple antigenic peptide system to produce antibodies against human heart fatty acid binding protein. Clin Chem 1997; 43:S245.

83. Christenson, R.H., Ohman, E.M., Califf, R.M., Armstrong, P.W., Newby, K.N., Granger, C.B., Peck, S., Duh, S.H., Katus, H.A., and Topol, E.J. Cardiac troponin T and cardiac troponin I compared in 755 acute coronary syndrome patients. Clin Chem 1997; 43:S117-S118.

84. Gordon, M.A. and Christenson, R.H. Free T3 assays on the axsym and imx systems evaluated. Clin Chem 1997; 43:S188-S189.

85. Alonsozana, G.L., Keffer, J.H., Olson, M., Stuart, J., and Christenson, R.H. Performance characteristics of a cardiac troponin I (ctnl) assay on the access system. Clin Chem 1997; 43:S158-S159.

86. Christenson, R.H., Alonsozana, G.L., and Duh, S.H. Characteristics of a more sensitive whole blood rapid assay for cardiac troponin T in cardiac ischemia patients. Clin Chem 1997; 43:S160-S161.

87. Alonsozana, G.L., Verma, D.K., and Christenson, R.H. Characterization of the axsym progesterone assay: correlation with the bmc es300 and the dpc coat-a-coat and determination or normal reference intervals. Clin Chem 1997; 43:S190.

88. Duh, S.H., Sloan, M., and Christenson, R.H. Normal reference intervals for serum cholinesterase and dibucaine number in a mixed population in the Baltimore area. Clin Chem 1997; 43:S124.

89. Azzazy, H.M.E., Cao, C.J., Christenson, R.H., and Eldefrawi, M.E. Cytosensor analysis: advantages of using human platelets toxicity. Clin Chem 1997; 43:S214.

90. Azzazy, H.M.E., Rafiq, N., Miller, D.M., and Christenson, R.H. Immunochemiluminescent assay for intraoperative measurement of parathyroid hormone. Clin Chem 1997; 43:S187.

91. Azzazy, H.M.E., Alonsozana, G.L., Jockle, G.A., and Christenson, R.H. Elevated cardiac troponin I with no myocardial necrosis in a patient with metastatic liver tumor. Clin Chem 1997; 43:S138.

92. Newby, K.N., Christenson, R.H., Peck, S., Katus, H.A., Hamm, C.W., Armstrong, P.W., and Ohman, E.M. Risk stratification by troponin T occurs within the first 30 days of acute coronary syndromes: one year results from the GUSTO-IIa troponin T substudy. Circulation 1997; 96:I-215-I216.

93. Christenson, R.H., Leino, V., and Bahr, R.D. Prodromal symptoms are an important predictor of infarct size category, independent of time to treatment and other clinical variables. Eur Hear J 1998; 19: 400.

94. Christenson, R.H., Demers, L.M., Goldsmith, B.M., Noel, S.A., and Duh, S.H. CK-MB mass measurement: Comparison of the johnson & johnson vitros Eci assay with the dade stratus II and abbott AxSym methods. Clin Chem 1998; 44:A123.

95. Alonsozana, G.L., Duh, S.H., and Christenson, R.H. Cardiac troponin I measurement with the abbott AxSYM: evaluation and comparison with the stratus and access systems. Clin Chem 1998; 44: A128.

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 31

96. Noel, S.A., Christenson, R.H., Demers, L.M., and Goldsmith, B.M. Third generation thyroid stimulating hormone enhanced chemiluminescence immunoassay performance on the ortho clinical diagnostics vitros Eci system. Clin Chem 1998; 44:A144.

97. Rosales, J.L., Foster, A.H., and Christenson, R.H. Quantitative relationship of catecholamine and cardiac troponin I release during cardiopulmonary bypass. Clin Chem 1998; 44:A162.

98. Azzazy, H.M.E., Magic, S.E., Gordon, M., and Christenson, R.H. Measurement of vitamin B12 on AxSYM: comparison with IMx and bio-rad RIA. Clin Chem 1998; 44:A89.

99. Goldsmith, B.M., Christenson, R.H., Demers, L.M., Duh, S.H., and Noel, S.A. Multi-center evaluation of thyroid assays on the vitros ECi immunoassay analyzer. Clin Chem 1998; 44:A143.

100. Azzazy, H.M.E., Magic, S.E., Gordon, M., and Christenson, R.H. Evaluation of the AxSYM folate: comparison with IMx and bio-rad RIA. Clin Chem 1998; 44:A167.

101. Demers, L.M., Noel, S.A., Goldsmith, B.M., and Christenson, R.H. Performance of an automated enhanced chemiluminescence immunoassay for FSH, LH, estradiol, and prolactin on the ortho clinical diagnostics vitros Eci system. Clin Chem 1998; 44:A61.

102. Koplen, B., Wu, A.H.B., Christenson, R.H., Valdes, Jr. R., Jortani, S.A., Johnson, N.A., Berg, N.A., and Apple, F.S. Clinical evaluation of the biosite triage cardiac panel for the simultaneous measurement of whole blood cTnl, CK-MB and myoglobin for detection of myocardial infarction. Clin Chem 1998; 44:A116.

103. Christenson, R.H., Apple, F.S., Azzazy, H.M.E., Bauer, R.S., Jacob, A., Landt, Y., Magneson, G., Vaidya, H., Wu, A.H.B. Standardization of CK-MB mass assays: the use of recombinant CK-MB as a reference material. Clin Chem 1998; 44:A119.

104. Apple, F., Murakimi, M., Panteghini, M., Christenson, R., Dati, F., and Wu, A. International survey of cardiac troponin users. Clin Chem 2000; 46:A76.

105. Wieczorak, S.J., Bailly, K.R., Thomas, P., Wu, A.H.B., Hager, D., Ferrier, A., Christenson, R., and Maisel, A. Clinical evaluation of the triage b-type natriuretic peptide assay for point of care testing of patients with congestive heart failure. Clin Chem 2000; 46:A77.

106. Christenson, R.H., Prosser, C., Ohman, E.M., Teo, K.K., Gibler, W.B., Langer, A., and Armstrong, P.W. Are results of rapid qualitative troponin I testing by clinical staff different from quantitative laboratory based testing. Clin Chem 2000; 46:A31.

107. Sanhai, W.R., Romero, L.F., Hickey, G., Ruttle, D., and Christenson, R.H. A multicenter evaluation of the revised cardiac troponin I assay on the opus plus system: A comparative study. Clin Chem 2000; 46:A86.

108. Sanhai, W.R., Bahr, R., Wentz, C., and Christenson, R.H. Bedside cardiac markers: Tracking time, bedside/lab results and cardiac troponin I+ patients. Clin Chem 2000; 46:A86.

109. Kahn, S.E., Apple, F.S., Bodor, G.S., Panteghini, M., Welch, M.H., Wu, A.H.B., Dalluge, J., and Christenson, R.H. Standardization of cardiac troponin I assays: Pilot evaluation of top ten candidate reference materials. Clin Chem 2000; 46:A89.

110. Christenson, R.H., Cervelli, D., Jones, H., Lesmerises, J., and Augustyn, J. Automated total iron binding capacity measurements on the Dimension system: Defining key performance characteristics. Clin Chem 2000; 46:A146.

111. Mahaffey, K.W., Bastos, E.M., Christenson, R.H., Every, N.R., Weaver, W.D., and Ohman, E.M. Peak creatine kinase and creatine kinase MB after acute myocardial infarction strongly correlate with ejection fraction and infarct size by nuclear imaging. Circulation 2000; 18:II-796.

112. Newby, K.N., Christenson, R.H., Ohman, E.M., Armstrong, P.W., Harrington, R.A., White, H.D., Irl, C., Califf, R.M., and Topol, E.J. Conversion of high-risk acute coronary syndromes to low(er) risk via the use of troponin and platelet glycoprotein IIb/IIIa blockade. Circulation 2000; 18:II-589.

113. Cantor WJ, Newby KN, Christenson RH, Tuttle RH, Armstrong PW, Califf RM, Ohman EM. Elevated troponin-I after percutaneous coronary intervention is a powerful prognostic indicator. Circulation 2000; 18:II-753.

114. Christenson, R.H., Jones, H., and Barger, J. Performance evaluation of the dimension Xpand clinical chemistry system. Clin Chem 2001; 47:A120.

115. Thompson, J.C., Christenson, R.H., Mandichak, J.J., Ross, C.T., and Trala, W.A. A photometric lithium assay for the dimension clinical chemistry system. Clin Chem 2001; 47:A82.

116. Sanhai, W.R., Duh, S.H., Sills, T.M., and Christenson, R.H. Cystatin C: A marker of graft rejection in renal transplant patients. Clin Chem 2001; 47: A154.

117. Duh, S.H. and Christenson, R.H. Effect of error in the estimated starting time of CMB elevation in

Robert H. Christenson, Ph.D., DABCC 7/11/07Curriculum Vitae – Continued Page 32

myocardial infarction on the curve fitting parameters using a long-normal model. Clin Chem 2001; 47:A213.

118. Kandzari, D.E., Chu, A., Brodie, B.R., Stuckey, Hermiller, Vetrovec, Hannon, K.L., Krucoff, M.W., Christenson, R.H., Gibbons, R., Sigmon, K.N., Collins, K., Harrington, R.A., and Califf, R.M.: Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention: Results of the LOWTEMP pilot study. AJC 2003; 92:1L.

119. Kanzari, D.E., Christenson, R.H., Harrington, R.A., and Tcheng, J.E.: Reduction of ischemic injury following coronary intervention: Results of the MC-1 to eliminate necrosis and damage trial (MEND-1). AJC 2003; 92:128L.

Letters to the Editor and Book Reviews

1.

Christenson, R.H., Miles, B., and Hammond, J.E. A comparison between the roche CEA and abbott CEA-RIA assay. Clin Chem 1982;28:561.

2.

Christenson, R.H., Miles, B., and Hammond, J.E. Further comparison of Abbott and Roche CEA assays. Clin Chem 1982; 28:1932.

3.

Christenson, R.H. and Brogden, A. Use of heparinized samples for salicylate determination with the DuPont aca validated. Clin Chem 1983;29:214-215.

4.

Martz, M.D., Odom, J.D., and Christenson, R.H. Proper instructions for preparing and ingesting suspensions of K-dur tablets in water. Am J Hosp Pharm 1989; 46:1341-1342.

5.

Christenson, R.H. and Gregory, L.C. Review for “Clinical Chemistry: Principles, Procedures, Correlations." Arch Pathol Lab Med 1993;117:775.

6.

Christenson, R.H. Response to letter titled: suggested non specificity of an immunochemical reagent used for quantifying the isoforms of creatine kinase-MB. J Clin Lab Anal 1996;10:55-56.

7.

Christenson, R.H. and Azzazy, H.M.E. Review for “All About Albumin.” Clin Chem 1997;43:2014-2015.

8.

Christenson, R.H. and Duh, S.H. Reply to increased concentrations of cardiac troponin I are equivalent to increased troponin T in identifying chest pain patients at short-term risk of myocardial infarction. Clin Chem 1998;44:1787-89.

9.

Azzazy, H.M.E. and Christenson, R.H. Review for “Clinical and Forensic Applications of Capillary Electrophoresis.” Anal Chem 2001; 57:837A

1010. deFilippi CR, Christenson RH. Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. JACC Heart Fail. 2015 Mar;3(3):253-6.